Treating Brain Injury

JP2024504651A5Active Publication Date: 2024-11-22IPSEN BIOPHARM LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023542964
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-01-15
Filing Date
2022-01-14
Publication Date
2024-11-22
Estimated Expiration
2042-01-14

AI Technical Summary

Technical Problem

Current treatments for brain disorders due to neuronal tissue damage, such as stroke, brain infections, and brain tumors, primarily focus on alleviating symptoms rather than promoting the repair of actual damage to neural tissue, and existing methods using Clostridial neurotoxins aim to suppress neuronal activity rather than enhance neuroimmune responses.

Method used

Administration of Clostridial neurotoxins, such as botulinum neurotoxin, to promote neuroimmune responses, specifically enhancing microglial activity and migration to sites of brain tissue damage, thereby facilitating the repair and clearance of damaged neural tissue.

Benefits of technology

The enhanced neuroimmune response leads to accelerated repair of neuronal tissue damage, improving recovery and prognosis by increasing microglial activity, density, and phagocytic activity at the site of injury, without the need for invasive surgical interventions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present invention provides a Clostridial neurotoxin for use in a method of treating a brain disorder in a patient by promoting a neuroimmune response.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to the treatment of brain disorders, more particularly by promoting the activity of a neuroimmune response at the site of brain tissue damage. [Background technology]

[0002] Brain disorders typically result from damage or injury to neuronal tissue, and such damage may be the primary cause of the symptoms underlying or defining neurological disorders. For example, when a patient suffers from a stroke, blood vessels in the brain become blocked or burst (e.g., hemorrhage). Therefore, nerve cells in the brain tissue that would otherwise be provided with healthy blood supply are damaged or die, impairing nerve cell activity. This lack of nerve activity can lead to symptoms including muscle weakness, paralysis, loss of sensation on one side of the body, dysarthria, delirium, vision problems, dizziness, loss of balance and coordination, and sudden severe headache in some hemorrhagic strokes.

[0003] In a further example, infectious diseases of the brain can lead to cell death underlying brain tissue damage. In bacterial meningitis, bacteria such as Streptococcus pneumoniae invade the meninges (membranes that help protect brain and spinal cord tissue from injury), and the subsequent damage to the meninges can result in neuronal cell death. When viruses reach and infect the brain, neuronal tissue damage can be caused by the virus's lytic effect on brain cells (e.g., in the case of cytomegalovirus), induced apoptosis (e.g., in the case of vesicular stomatitis virus (VSV)), or secondary damage due to the release of glutamate, DNA, and other inducers of brain damage.

[0004] In patients with brain cancer, tumors can cause physical damage to the brain's nerve tissue by pushing and putting pressure on nerve cells. Damage can also be caused by tumor movement in the case of metastasis.

[0005] Although treatment options exist to alleviate patient symptoms resulting from such nerve damage, relatively few of these work in a way that promotes (or otherwise facilitates) repair of the actual damage to nerve tissue. For example, in stroke, the only treatment options are local recanalization and systemic fibrinolysis, which aim to restore blood flow to alleviate nerve damage. However, such treatment options are not suitable for all patients and / or may cause even further damage.

[0006] The present invention solves one or more of the problems mentioned above. Summary of the Invention

[0007] More particularly, the present invention is based on the surprising finding that clostridial neurotoxins, when administered to patients suffering from nervous system tissue damage induced by brain injury, stimulate immune cell (e.g., neuroimmune) activity in the area of ​​neuronal tissue damage. In other words, surprisingly, clostridial neurotoxins can be used to stimulate neuroimmune activity as a means to prevent / repair neuronal tissue damage in patients suffering from brain injury.

[0008] More specifically, it is demonstrated herein that the activity of microglia (located near areas of brain tissue damage) is enhanced in patients receiving a dose of a Clostridial neurotoxin. Microglia are key macrophages in the brain involved in clearing damaged neural tissue and foreign bodies. This demonstrates the surprising utility of the Clostridial neurotoxins introduced below.

[0009] Bacteria of the Clostridia class produce highly potent and specific protein toxins that can (temporarily) impair the function of neurons and other cells to which they are delivered. Examples of such clostridial toxins include the neurotoxins produced by C. tetani (TeNT) and C. botulinum (BoNT) serotypes A-G and X (see WO 2018 / 009903 A2), as well as those produced by C. baratii and C. butyricum.

[0010] Some of the most potent toxins known are members of the Clostridial neurotoxin family. For example, botulinum neurotoxins have median lethal doses (LD50s) in mice ranging from 0.5 to 5 ng / kg, depending on the serotype. 50 ) value. Both tetanus and botulinum toxins act by inhibiting the function of affected neurons, specifically the release of neurotransmitters. Botulinum toxin acts at the neuromuscular junction and inhibits cholinergic transmission in the peripheral nervous system, while tetanus toxin acts in the central nervous system.

[0011] In nature, clostridial neurotoxins are synthesized as single-chain polypeptides, which are post-translationally modified by a proteolytic cleavage event to form two polypeptide chains joined together by a disulfide bond. Cleavage occurs at a specific cleavage site, often referred to as the activation site, which is located between the cysteine ​​residues that provide the interchain disulfide bond. It is this two-chain form that is the active form of the toxin. The two chains are designated heavy chains (H chains), with a molecular mass of approximately 100 kDa, and light chains (L chains), with a molecular mass of approximately 50 kDa. The H chains are connected to an N-terminal transition component (H N domain) and a C-terminal targeting component (H C The cleavage site is located between the L chain and translocation domain components. C Following binding of the domains and internalization of the bound toxin into the cell via endosomes, H NThe domain translocates the L chain across the endosomal membrane into the cytosol, where the L chain provides the protease function (also known as a non-cytotoxic protease).

[0012] Clostridial neurotoxins provide non-cytotoxic protease activity. Non-cytotoxic proteases act by proteolytically cleaving intracellular transport proteins known as SNARE proteins (e.g., SNAP-25, VAMP, or syntaxin). The acronym SNARE comes from the term soluble NSF adhesion receptor, where NSF stands for N-ethylmaleimide-sensitive factor. SNARE proteins are essential for intracellular vesicle fusion and therefore for the secretion of molecules from cells via vesicular transport. The protease function is a zinc-dependent endopeptidase activity and exhibits high substrate specificity for SNARE proteins. Therefore, once delivered to the desired target cell, the non-cytotoxic protease can inhibit cellular secretion from the target cell. The light-chain proteases of clostridial neurotoxins are non-cytotoxic proteases that cleave SNARE proteins.

[0013] Given the ubiquitous nature of SNARE proteins, clostridial neurotoxins, such as botulinum toxin, have been successfully employed in a wide range of therapeutic applications. The present inventors have demonstrated the surprising utility of clostridial neurotoxins in treating brain disorders by promoting neuroimmune activity.

[0014] A common feature of brain disorders is that the host's own neuroimmune response responds to the damage behind the brain injury by clearing and / or preventing brain tissue damage. In the case of infectious diseases, there can be an innate response in which (for example) macrophages (e.g., microglia) migrate to the site of infection and phagocytose the invading pathogen. Macrophages are a type of immune system white blood cell that engulfs and digests cellular debris, foreign material, microorganisms, cancer cells, and other non-host factors in a process called phagocytosis.

[0015] When neuronal cell death occurs, microglia respond by migrating to the lesion (injury) site, where they phagocytose cellular debris. Therefore, microglia can be reactive to brain damage by removing brain tissue caused by physical injury (e.g., brain tumors). For example, microglial phagocytosis can clear dead cells. These may release otherwise toxic substances into their environment, thereby exacerbating tissue damage. Microglia have also been reported to play a direct role in defense against brain tumors. Furthermore, microglia have been reported to be involved in "synaptic pruning," in which they engulf synaptic material and help prevent synaptic abnormalities seen in some neurodevelopmental disorders.

[0016] Therefore, by promoting neuroimmune activity in response to neuronal tissue damage, clostridial neurotoxin administration advantageously finds utility in treating brain disorders. DETAILED DESCRIPTION OF THE INVENTION

[0017] A general aspect of the invention provides either: - Clostridial neurotoxins for use in methods for treating brain disorders; - a method of treating a brain disorder in a patient, the method comprising administering to the patient a Clostridial neurotoxin; - Use of a Clostridial neurotoxin in the manufacture of a medicament for treating a brain disorder in a patient.

[0018] A general aspect of the invention provides either: - Clostridial neurotoxins for use in methods for treating brain tissue damage (e.g., neuronal tissue damage); - a method of treating brain tissue damage (e.g., neuronal tissue damage) in a patient, the method comprising administering to the patient a Clostridial neurotoxin; - Use of a Clostridial neurotoxin in the manufacture of a medicament for treating brain tissue damage (e.g., neuronal tissue damage) in a patient.

[0019] A general aspect of the invention provides either: - Clostridial neurotoxins for use in methods for treating brain infections; - a method of treating a brain infection in a patient, the method comprising administering to the patient a Clostridial neurotoxin; - Use of a Clostridial neurotoxin in the manufacture of a medicament for treating a brain infection in a patient.

[0020] Clostridial neurotoxins can treat brain disorders by promoting a neuroimmune (e.g., microglial) response. For example, clostridial neurotoxins can be for use in methods of treating brain disorders by promoting a neuroimmune (e.g., microglial) response to treat brain disorders. Clostridial neurotoxins can treat brain tissue damage (e.g., neuronal tissue damage) by promoting a neuroimmune (e.g., microglial) response. For example, clostridial neurotoxins can be for use in methods of treating brain tissue damage (e.g., neuronal tissue damage) by promoting a neuroimmune (e.g., microglial) response to treat brain tissue damage (e.g., neuronal tissue damage).

[0021] Clostridial neurotoxins can treat brain disorders by promoting microglial activity (e.g., in response to neuronal tissue damage). For example, clostridial neurotoxins can be used in methods for treating brain disorders by promoting microglial activity to treat brain disorders. Clostridial neurotoxins can treat brain tissue damage (e.g., neuronal tissue damage) by promoting microglial activity (e.g., in response to neuronal tissue damage). For example, clostridial neurotoxins can be used in methods for treating brain tissue damage (e.g., neuronal tissue damage) by promoting microglial activity to treat brain tissue damage (e.g., neuronal tissue damage).

[0022] Clostridial neurotoxins can treat brain disorders by promoting microglial migration to sites of brain tissue damage (e.g., neuronal tissue damage). For example, clostridial neurotoxins can be used in methods of treating brain disorders by promoting microglial migration to sites of brain tissue damage. Clostridial neurotoxins can treat brain tissue damage (e.g., neuronal tissue damage) by promoting microglial migration to sites of brain tissue damage (e.g., neuronal tissue damage). For example, clostridial neurotoxins can be used in methods of treating brain tissue damage (e.g., neuronal tissue damage) by promoting microglial migration to sites of brain tissue damage (e.g., neuronal tissue damage) to treat brain tissue damage.

[0023] Clostridial neurotoxins can treat brain disorders by promoting microglial cell phagocytic activity at the site of brain tissue damage (e.g., neuronal tissue damage). For example, clostridial neurotoxins can be used in methods for treating brain disorders by promoting microglial cell phagocytic activity at the site of brain tissue damage (e.g., neuronal tissue damage). Clostridial neurotoxins can treat brain tissue damage (e.g., neuronal tissue damage) by promoting microglial cell phagocytic activity at the site of brain tissue damage (e.g., neuronal tissue damage). For example, clostridial neurotoxins can be used in methods for treating brain tissue damage (e.g., neuronal tissue damage) by promoting microglial cell phagocytic activity at the site of brain tissue damage (e.g., neuronal tissue damage) to treat brain tissue damage.

[0024] Clostridial neurotoxins can treat brain disorders by promoting microglial clearance of cellular debris at sites of brain tissue damage (e.g., neuronal tissue damage). For example, clostridial neurotoxins can be for use in methods of treating brain disorders by promoting microglial clearance of cellular debris at sites of brain tissue damage (e.g., neuronal tissue damage). Clostridial neurotoxins can treat brain tissue damage (e.g., neuronal tissue damage) by promoting microglial clearance of cellular debris at sites of brain tissue damage (e.g., neuronal tissue damage). For example, clostridial neurotoxins can be for use in methods of treating brain tissue damage (e.g., neuronal tissue damage) by promoting microglial clearance of cellular debris at sites of brain tissue damage (e.g., neuronal tissue damage) to treat brain tissue damage.

[0025] Clostridial neurotoxins can treat brain disorders by promoting microglial responses to infection. For example, Clostridial neurotoxins can be used in methods for treating brain disorders by promoting microglial responses to infection to treat brain disorders. Clostridial neurotoxins can treat brain tissue damage (e.g., neuronal tissue damage) by promoting microglial responses to infection. For example, Clostridial neurotoxins can be used in methods for treating brain tissue damage (e.g., neuronal tissue damage) by promoting microglial responses to infection to treat brain tissue damage (e.g., neuronal tissue damage).

[0026] Clostridial neurotoxins can treat brain infections by promoting a neuroimmune (e.g., microglial) response. For example, Clostridial neurotoxins can be for use in methods of treating brain infections by promoting a neuroimmune (e.g., microglial) response to treat brain infections. Clostridial neurotoxins can treat brain infections by promoting a neuroimmune (e.g., microglial) response. For example, Clostridial neurotoxins can be for use in methods of treating brain infections by promoting a neuroimmune (e.g., microglial) response to treat brain infections.

[0027] Clostridial neurotoxins can treat brain infections by promoting microglial cell activity (e.g., in response to infection). For example, Clostridial neurotoxins can be used in methods for treating brain infections by promoting microglial cell activity to treat brain infections. Clostridial neurotoxins can treat brain infections by promoting microglial cell activity (e.g., in response to infection). For example, Clostridial neurotoxins can be used in methods for treating brain infections by promoting microglial cell activity to treat brain infections.

[0028] Clostridial neurotoxins can treat brain infections by promoting microglial cell migration to the site of the brain infection.For example, Clostridial neurotoxins can be used in a method for treating brain infections by promoting microglial cell migration to the site of the brain infection.Clostridial neurotoxins can treat brain infections by promoting microglial cell migration to the site of the brain infection.For example, Clostridial neurotoxins can be used in a method for treating brain infections by promoting microglial cell migration to the site of the brain infection to treat brain infections.

[0029] Clostridial neurotoxins can treat brain infections by promoting microglial cell phagocytic activity at the site of brain infection.For example, Clostridial neurotoxins can be used in a method for treating brain infections by promoting microglial cell phagocytic activity at the site of brain infection.Clostridial neurotoxins can treat brain infections by promoting microglial cell phagocytic activity at the site of brain infection.For example, Clostridial neurotoxins can be used in a method for treating brain infections by promoting microglial cell phagocytic activity at the site of brain infection to treat brain infections.

[0030] Clostridial neurotoxins can treat brain infections by promoting microglial clearance of cellular debris at the site of the brain infection. For example, Clostridial neurotoxins can be for use in methods of treating brain infections by promoting microglial clearance of cellular debris at the site of the brain infection. Clostridial neurotoxins can treat brain infections by promoting microglial clearance of cellular debris at the site of the brain infection. For example, Clostridial neurotoxins can be for use in methods of treating brain infections by promoting microglial clearance of cellular debris at the site of the brain infection to treat brain infections.

[0031] Clostridium neurotoxin can treat brain infection by promoting microglial response to infection.For example, Clostridium neurotoxin can be used in the method for treating brain infection by promoting microglial response to infection to treat brain damage.Clostridium neurotoxin can treat brain infection by promoting microglial response to infection.For example, Clostridium neurotoxin can be used in the method for treating brain infection by promoting microglial response to infection to treat brain infection.

[0032] In one embodiment, a Clostridial neurotoxin is provided for use in a method for treating a brain disorder in a patient by promoting a neuroimmune response. In other words, one embodiment provides a Clostridial neurotoxin for use in promoting a neuroimmune response to treat a brain disorder.

[0033] In a related embodiment, a method is provided for treating a brain disorder in a patient by promoting a neuroimmune response, the method comprising administering a Clostridial neurotoxin to the patient. In other words, one embodiment provides a method for promoting a neuroimmune response to treat a brain disorder in a patient, the method comprising administering a Clostridial neurotoxin to the patient.

[0034] In a further embodiment, there is provided the use of a Clostridial neurotoxin in the manufacture of a medicament for treating a brain disorder in a patient by promoting a neuroimmune response. In other words, one embodiment provides the use of a Clostridial neurotoxin in the manufacture of a medicament for promoting a neuroimmune response to treat a brain disorder in a patient.

[0035] Therefore, the clostridial neurotoxins described herein promote neuroimmune responses. As such, the clostridial neurotoxin(s) find utility in treating brain disorders. As used herein, the term "brain disorder" (which may be used synonymously with the term "brain damage" herein) refers to a disorder that can be treated by promoting a patient's neuroimmune response. Brain disorders can be caused by brain tissue damage (e.g., neuronal tissue damage). Additionally or alternatively, brain disorders can cause neuronal tissue damage. Therefore, promoting neuroimmune response activity can have the effect of promoting repair of neuronal tissue damage and thus enhancing recovery from brain disorders.

[0036] The term "brain tissue damage" may be used interchangeably herein with the term "brain tissue injury." Similarly, the term "neuronal tissue damage" may be used interchangeably herein with the term "neuronal tissue injury."

[0037] In one embodiment, the neuroimmune response can be defined as a microglial response. Therefore, the clostridial neurotoxin promotes microglial activity in the brain.

[0038] Microglia represent a population of macrophage-like cells in the central nervous system, particularly the brain. They are typically considered immune sentinels capable of orchestrating potent inflammatory responses. Microglia are also involved in synapse organization, trophic support for neurons during development, phagocytosis of apoptotic cells in the developing brain, myelin turnover, control of neuronal excitability, phagocytic debris removal, and brain protection and repair.

[0039] In one embodiment, a Clostridial neurotoxin is provided for use in a method for treating a brain disorder in a patient by promoting microglial activity (e.g., in the brain). In other words, one embodiment provides a Clostridial neurotoxin for use in promoting microglial activity (e.g., in the brain) to treat a brain disorder. In the context of brain tissue (e.g., neuronal tissue) damage, microglial activity can be promoted to repair (or clear) damaged tissue. Non-limiting examples of microglial cell (e.g., macrophage) activity include phagocytic activity (e.g., clearing cellular debris) at the site of nerve or brain tissue damage.

[0040] Therefore, without wishing to be bound by theory, one observed effect on which the present invention is based is the ability to promote the role of the neuroimmune response in responding to neuronal damage (which may be caused by or actually cause brain damage) and clear / repair such damage. Therefore, although it is understood that an individual's endogenous neuroimmune response may already be engaged in the action and function of combating neuronal damage, the present invention provides an advantageous "boost" to such a response, which may correlate with a faster development of the neuroimmune response, increased recruitment of neuroimmune cells to the site of neuronal damage, and / or increased activity of neuroimmune cells toward treating the damage. Enhanced recovery from injury (e.g., neuronal tissue injury) may follow as an outcome.

[0041] To demonstrate this technical effect, the inventors coupled "two-photon" imaging and laser technology with a transgenic mouse model, enabling high-resolution tracking of the activity of the animal's own microglial cells directly in an in vivo brain setting. The animal model (CX3CR1-GFP mice) expresses GFP in their microglial cells, allowing the cells to be imaged and tracked by fluorescence microscopy.

[0042] To induce neuronal damage comparable to that occurring in the "brain disorders" described herein (e.g., in brain infections), the inventors employed two-photon microscopy technology to provide a distinct focus of laser-induced injury in the brain. More specifically, a micrometer-sized region of interest (ROI) was selected on the focal plane at a depth of 25-35 micrometers from the cortical surface, and laser intensity was applied to this focal region to provide a localized, distinct region of damaged brain tissue. Such a distinct region of brain tissue damage also allows for examination of microglial cells surrounding a spatially controlled area of ​​induced tissue damage, mimicking what may occur due to brain hypoxia (e.g., after a stroke), a growing brain tumor, and / or post-infectious swelling (e.g., encephalitis).

[0043] As demonstrated in the Examples section, microglia responded to this injury by migrating to specific sites of injury and adopting a phenotype consistent with phagocytic activity. Surprisingly, however, such activity was significantly increased in mice administered a clostridial neurotoxin (e.g., BoNT / A), demonstrating the unexpected technical effect of the clostridial neurotoxin in promoting a patient's neuroimmune response to brain injury.

[0044] Therefore, clostridial neurotoxins find utility in enhancing recovery from brain (e.g., neuronal tissue) damage, and can therefore be used to treat distinct clinical subsets of patients requiring brain damage repair. Advantageously, such repair is orchestrated by the patient's own neuroimmune response, which is enhanced / promoted after administration of a clostridial neurotoxin. Step(s) toward providing this effect, i.e., administration of a clostridial neurotoxin by a route such as intracortical injection, is a relatively achievable and non-invasive technique (relative to brain surgery). Therefore, the need for complex surgical intervention (brain surgery) can be alleviated.

[0045] Following from the indication that patients suffering from brain damage are particularly suitable for treatment according to the present invention, a still further clinical subset (or sub-subset) of such patients may be represented by patients in whom the "endogenous" level of neuroimmune response activity is insufficient to treat tissue damage. In other words, the demonstrated technical effect(s) of the present invention provided by administration of a Clostridial neurotoxin provides particular clinical utility in patients who would benefit from a "boost" of their neuroimmune response (against injury) to improve their prognosis relative to what would follow if relying on the patient's endogenous level of neuroimmune response.

[0046] Such utility contrasts with the alleged function of clostridial neurotoxins in prior art methods employing such neurotoxins to treat brain disorders. Because clostridial neurotoxins function to cleave SNARE proteins and inhibit neurotransmitter secretion (as described in detail elsewhere herein), prior art methods have sought to suppress brain neuronal activity by administering clostridial neurotoxins to achieve neurotoxin-mediated prevention of neurotransmitter release. For example, it has been proposed to target neurotoxins to brain regions that exhibit "abnormal" activity in epilepsy to suppress such abnormal activity that might otherwise correlate with seizures. Other prior art has proposed targeting (and inhibiting) otherwise overactive inhibitory cholinergic neurons (e.g., in the striatum of the brain) to suppress neuronal activity correlated with movement disorders.

[0047] However, such prior art methods did not involve repair of tissue damage, much less rely on the Clostridial neurotoxin-induced promotion of neuroimmune cell activity. Instead of suppressing neuronal activity, the present invention is directed to the removal / repair of damaged neurons. Therefore, the present invention is directed to treating brain disorders by treating brain tissue damage; more specifically, by promoting neuroimmune cell activity in treating such damage.

[0048] Therefore, the inventors have not only identified a new technical field of application of Clostridial neurotoxins (i.e., brain disorders associated with brain tissue damage), but also identified an unexpected technical effect in said field (i.e., promotion of neuroimmune responses). In a related embodiment, a method of treating a brain disorder in a patient by promoting microglial activity (e.g., in the brain) is provided, the method comprising administering a Clostridial neurotoxin to the patient. In other words, one embodiment provides a method for promoting microglial activity (e.g., in the brain) to treat a brain disorder in a patient, the method comprising administering a Clostridial neurotoxin to the patient.

[0049] In a further aspect, there is provided the use of a Clostridial neurotoxin in the manufacture of a medicament for treating a brain disorder in a patient by promoting microglial activity (e.g., in the brain). In other words, one aspect provides the use of a Clostridial neurotoxin in the manufacture of a medicament for promoting microglial activity (e.g., in the brain) to treat a brain disorder in a patient.

[0050] Therefore, the clostridial neurotoxins described herein promote a neuroimmune response. As such, the clostridial neurotoxin(s) find utility in treating brain disorders. As used herein, the term "brain disorder" (which may be used interchangeably with the term "brain damage") refers to a disorder that can be treated by promoting a neuroimmune response in a patient.

[0051] The term "neuroimmune response" refers to the response of a patient's neuroimmune system to brain damage. For example, as used herein, the term "neuroimmune response" can refer to the response of the neuroimmune system to brain tissue damage (e.g., neuronal tissue damage), brain infection, and / or brain tumor (said neuronal damage can be caused by brain infection and / or brain tumor). The neuroimmune response can be to prevent brain tissue damage (e.g., neuronal tissue damage). Additionally or alternatively, the neuroimmune response can be to repair brain tissue damage (e.g., neuronal tissue damage). The term "neuroimmune response" is not intended to be limited to responses to infection, but also encompasses the response of the neuroimmune system to brain tissue damage (e.g., neuronal tissue damage) caused by alternative disorders (e.g., stroke). Indeed, physical injury and necrosis can also trigger a neuroimmune response. In embodiments where the brain damage is (or is caused by) an infectious disease, the neuroimmune response can be a response to infection.

[0052] The neuroimmune system is primarily composed of glial cells, including astrocytes, microglia, and oligodendrocytes, with microglial cells (e.g., macrophages) in particular representing the key immune cells of this system in the brain. As described above, the neuroimmune response referred to herein can be defined as a microglial response.

[0053] The term "promoting a neuroimmune response" can mean that the Clostridial neurotoxin (or fragment thereof) of the present invention initiates a neuroimmune response in a patient with a brain injury, e.g., where a neuroimmune response would not be generated or where the "intrinsic" neuroimmune response is not strong enough to overcome the brain injury (e.g., neuronal tissue damage). Thus, although the present invention is based on the administration of a Clostridial neurotoxin in the methods described herein, it may be more accurate to say that a "neuroimmune response" (preferably microglial cells) achieves treatment of, e.g., brain tissue damage; in this context, the Clostridial neurotoxin promotes the role of the neuroimmune response (e.g., microglial cells) in treating brain tissue damage.

[0054] The term "promoting a neuroimmune response" can mean that a clostridial neurotoxin of the present invention accelerates the development of a neuroimmune response in a patient with a brain injury, for example, where a neuroimmune response would not have been initiated. In a preferred embodiment, the term "promoting a neuroimmune response" can mean that a clostridial neurotoxin of the present invention increases the level of the neuroimmune response. The increase can be compared to the level of the neuroimmune response in the absence of the clostridial neurotoxin of the present invention. In one embodiment, the neuroimmune response can remove damaged brain tissue (e.g., damaged neuronal tissue or nerves) and enable the reconstruction of damaged neuronal circuits, thereby restoring activity and / or neuronal transmission in a neuronal network or population.

[0055] In certain embodiments, the neuroimmune response comprises activation of microglial cell(s) (e.g., macrophages) as measured by: 1) a change in microglial cell density at the site of brain tissue damage (e.g., neuronal tissue damage), 2) a change in the level of microglial cell migration (e.g., a change in microglial cell sphericity) to the site of brain tissue damage (e.g., neuronal tissue damage), 3) a change in the level of microglial process outgrowth toward the site of brain tissue damage (e.g., neuronal tissue damage), and / or 4) a change in the level of microglial cell phagocytic activity (e.g., clearance of cellular debris) at the site of brain tissue damage (e.g., neuronal tissue damage) in the presence of a Clostridial neurotoxin of the invention compared to microglial activity in the absence of the Clostridial neurotoxin of the invention.

[0056] It should be pointed out that neuroimmune cell (particularly microglial cell) activity is expected to increase in response to neuronal tissue injury even in "naive" (e.g., untreated with agents such as clostridial neurotoxins) brains, consistent with the role of such cells in central nervous system repair after injury. Despite this, "control" experiments (e.g., vehicle-only controls) provided herein demonstrate that administration of clostridial neurotoxins enables injury-induced activation levels of neuroimmune cell activity that exceed levels otherwise endogenous to the subject (even in the presence of the exact same type of injury). Thus, in promoting neuroimmune cell activity (in response to injury), the present invention "boosts" the activity of such cells to combat / repair damage caused by brain injury, further enhancing patient healing and mitigating further damage caused by the presence of damaged tissue (e.g., necrotic material). For example, the methods of the present invention can be utilized to treat patients whose "normal" (or "endogenous") levels of neuroimmune cell activity (in response to injury) are insufficient to combat / repair neuronal tissue damage underlying (or caused by) brain damage.

[0057] By "boosting" the neuroimmune response to increase its activity by a certain level, there may be a concomitant increase in the level of "damage repair." A positive outcome may be followed by a subsequent (e.g., correlated) increase in the patient's prognosis for recovery (or survival). For example, by "boosting" the neuroimmune response to increase its activity by, for example, 5%, there may be a concomitant 5% increase in the level of "damage repair"; a subsequent 5% increase in the patient's prognosis for recovery (or survival) may be followed.

[0058] For example, the neuroimmune response may be increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (preferably at least 5%) or more in the presence of a Clostridial neurotoxin of the present invention when compared to the neuroimmune response in the absence of the Clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0059] The neuroimmune response may be increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70% (preferably at least 30%) in the presence of a Clostridial neurotoxin of the present invention when compared to the neuroimmune response in the absence of the Clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the neuroimmune response may be increased by at least 100%, 150%, or 200% in the presence of a Clostridial neurotoxin of the present invention when compared to the neuroimmune response in the absence of the Clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0060] Neuroimmune response can refer to microglial activity.For example, the neuroimmune response referred to herein can preferably comprise or consist of microglial activity.In one embodiment, clostridial neurotoxin promotes microglial activity in the brain.For example, when compared with the microglial activity in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide), microglial activity can be increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (preferably at least 5%) or more in the presence of the clostridial neurotoxin of the present invention.

[0061] For example, microglial activity may be increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70% (preferably at least 30%) in the presence of a clostridial neurotoxin of the present invention when compared to microglial activity in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, microglial activity may be increased by at least 100%, 150%, or 200% in the presence of a clostridial neurotoxin of the present invention when compared to microglial activity in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0062] The term "microglial activity" (also known as "microglial cell activity" or "microglial activity") used herein refers to the functions undertaken by microglial cells in response to the presence of damage, such as brain tissue injury, infection, and / or tumors. Microglia are sensitive to neuronal tissue damage, and such damage, such as by injury / infection / neurotoxic factors, stimulates microglia (e.g., to become activated), which migrate to the site of injury. A stronger microglial response typically correlates with a higher number of microglial cells migrating to the lesion (site of injury), such that the density of microglial cells at the site of injury can increase in line with the rate / level of response.

[0063] In one embodiment, microglial activity can be measured based on the density of microglial cells at the site of brain tissue damage (e.g., neuronal tissue damage). Clostridial neurotoxins can promote "microglial cell density levels" at the site of brain tissue damage (e.g., neuronal tissue damage), such as brain tissue damage caused by a brain disorder described herein.

[0064] The term "microglial cell density level" refers to the number of microglial cells in a given site / given area, with increasing density correlating with increasing cell number.

[0065] A clostridial neurotoxin can promote microglial cell density levels at the site of infection (e.g., the site of brain tissue damage caused by the infection). A clostridial neurotoxin can promote microglial cell density levels at the site of a brain tumor (or the site of brain tissue damage caused by a brain tumor). A clostridial neurotoxin can promote microglial cell density levels at the site of a stroke (or the site of brain tissue damage caused by a stroke). For example, the microglial cell density level can be increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (preferably at least 5%) or more in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell density level in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0066] For example, the microglial cell density level (in any of the embodiments described herein) may be increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70% (preferably at least 30%) in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell density level in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the microglial cell density level may be increased by at least 100%, 150%, or 200% in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell density in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0067] Therefore, by increasing the level of microglial cell density at the site of injury (neuronal injury), the number of microglial cells "available" to fight / repair the injury increases. For example, due to the presence of an increased number of microglia at the site of injury / injury, an amount of microglial phagocytosis of damaged tissue (and / or pathogens) may ensue. Thus, a concomitant increase in the level of (injury) repair may ensue. This provides a treatment for brain disorders accordingly.

[0068] In one embodiment, microglial activity can be measured based on the level of "microglial cell migration" to a site of brain tissue damage (e.g., neuronal tissue damage). In one embodiment, a clostridial neurotoxin promotes microglial cell migration to a site of brain tissue damage (e.g., neuronal tissue damage). A clostridial neurotoxin can promote microglial cell migration to a site of infection (or a site of brain tissue damage caused by an infection). A clostridial neurotoxin can promote microglial cell migration to a site of brain tumor (or a site of brain tissue damage caused by a brain tumor). A clostridial neurotoxin can promote microglial cell density levels at a site of stroke (or a site of brain tissue damage caused by a stroke).

[0069] The term "microglial cell migration" refers to the active (directional) movement of microglial cells toward sites described herein (e.g., sites of brain tissue injury, infection, tumors), e.g., in response to stimulatory factor release from dying cells. The term "microglial cell migration" may be used interchangeably herein with the term "microglial migration."

[0070] For example, the microglial cell migration may be increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (preferably at least 5%) in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell density level in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). For example, the microglial cell migration (in any of the embodiments described herein) may be increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70% (preferably at least 30%) in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell migration in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the microglial cell migration may be increased by at least 80%, 90%, or 100% in the presence of a Clostridial neurotoxin of the present invention when compared to microglial cell migration in the absence of the Clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the microglial cell migration may be increased by at least 110%, 125%, or 150% in the presence of a Clostridial neurotoxin of the present invention when compared to microglial cell migration in the absence of the Clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0071] By increasing microglial cell migration toward the sites described herein (e.g., sites of brain tissue injury, infection, tumor), the number of microglial cells "available" to fight / repair the injury (or infection) increases. For example, due to the presence of increased numbers of microglia at the site of injury / injury, the amount of microglial phagocytosis of the damaged tissue (and / or pathogens) may ensue. Thus, a concomitant increase in the level of (injury) repair may ensue. Treatment of brain disorders may thus be provided.

[0072] A suitable readout of cell migration is the sphericity of microglial cells. Therefore, the sphericity index of microglial cells (more typically, the mean sphericity index of microglial cells) can be detected. Here, a decrease in the sphericity index correlates with increased elongation (elongated shape) of the microglial cell(s). For example, they become motile and migrate toward the site of brain injury. The sphericity index can be defined as the ratio of the squared volume (V) of a microglial cell to the cube of the surface area (S) covered by the microglial cell: Sphericity=36πV 2 / S 3 For example, the sphericity of microglial cell(s) may be reduced by at least 1%, 2%, 5%, 10%, 15%, 20%, 25%, or 30% (preferably at least 10%) in the presence of a clostridial neurotoxin of the present invention when compared to the sphericity of microglial cell(s) in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the sphericity of microglial cell(s) may be reduced by at least 35%, 40%, or 50% in the presence of a clostridial neurotoxin of the present invention when compared to the sphericity of microglial cell(s) in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0073] Microglia are highly dynamic cells that interact with neurons and non-neuronal cells. They patrol the brain parenchyma by continuous process extension and retraction. For example, microglia can extend their processes toward the damaged area in response to stimulation of the metabotropic ATP receptor P2Y (12), e.g., by ATP released from damaged tissue.

[0074] In one embodiment, microglial activity can be measured based on the level of microglial process outgrowth toward sites of brain tissue damage (e.g., neuronal tissue damage). In one embodiment, a clostridial neurotoxin promotes microglial process outgrowth toward sites of brain tissue damage (e.g., neuronal tissue damage). A clostridial neurotoxin can promote microglial process outgrowth toward sites of infection (or sites of brain tissue damage caused by infection). A clostridial neurotoxin can promote microglial process outgrowth toward sites of brain tumors (or sites of brain tissue damage caused by brain tumors). A clostridial neurotoxin can promote microglial process outgrowth toward sites of stroke (or sites of brain tissue damage caused by stroke).

[0075] The term "microglial process outgrowth" refers to an increase in the length of the extended processes of microglial cells, which, among other functions, enable the cells to migrate, e.g., by chemotaxis. For example, the number and / or length of microglial processes can be increased in the methods of the invention.

[0076] For example, the microglial process outgrowth may be increased by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% (preferably at least 5%) in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell density level in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). For example, the microglial process outgrowth (in any of the embodiments described herein) may be increased by at least 5%, 10%, 20%, 30%, 40%, 50%, 60%, or 70% (preferably at least 60%) in the presence of a clostridial neurotoxin of the present invention when compared to the microglial process outgrowth in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the microglial process outgrowth may be increased by at least 80%, 90%, or 100% in the presence of a Clostridial neurotoxin of the present invention when compared to microglial process outgrowth in the absence of the Clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the microglial process outgrowth may be increased by at least 125%, 150%, or 200% in the presence of a Clostridial neurotoxin of the present invention when compared to microglial process outgrowth in the absence of the Clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0077] In one embodiment, microglial activity can be measured based on the level of microglial cell phagocytic activity at the site of brain tissue damage (e.g., neuronal tissue damage). Clostridial neurotoxins can promote microglial cell phagocytic activity at the site of brain tissue damage (e.g., neuronal tissue damage). Clostridial neurotoxins can promote microglial cell phagocytic activity at the site of infection (or the site of brain tissue damage caused by infection). Clostridial neurotoxins can promote microglial cell phagocytic activity at the site of brain tumor (or the site of brain tissue damage caused by brain tumor). Clostridial neurotoxins can promote microglial cell phagocytic activity at the site of stroke (or the site of brain tissue damage caused by stroke).

[0078] The term "microglial cell phagocytic activity" (also known as "microglial phagocytic activity") refers to the engulfment of cellular material by microglia (including the engulfment of foreign bodies such as cellular debris and microorganisms after brain tissue injury). When engulfing cellular debris, the term "microglial cell phagocytic activity" may be used synonymously herein with the term "microglial clearance of cellular debris." Phagocytic activity may be measured by detecting the clearance of cellular debris at the site of brain tissue injury.

[0079] The term "cellular debris" preferably refers to cellular components released from dead neurons.

[0080] For example, the microglial cell phagocytic activity (in any of the embodiments described herein) may be increased by at least 10%, 20%, 30%, 40%, 50%, 60%, or 70% (preferably at least 30%) in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell phagocytic activity in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the microglial cell phagocytic activity may be increased by at least 80%, 90%, or 100% in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell phagocytic activity in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide). In some embodiments, the microglial cell phagocytic activity may be increased by at least 125%, 150%, or 200% in the presence of a clostridial neurotoxin of the present invention when compared to the microglial cell phagocytic activity in the absence of the clostridial neurotoxin of the present invention (or in the presence of an alternative polypeptide).

[0081] The present inventors have surprisingly demonstrated that clostridial neurotoxin-mediated stimulation of the neuroimmune response can occur rapidly, i.e., promote the early onset of a response to injury. Furthermore, the stimulated response can be acute, e.g., attenuated once the tissue injury / invasive insult has cleared, mitigating any negative effects of a long-term "hyperactive" response.

[0082] In one embodiment, the neuroimmune response is enhanced ≦2 minutes, ≦4 minutes, ≦6 minutes, ≦8 minutes, ≦10 minutes, ≦12 minutes, ≦14 minutes, ≦16 minutes, ≦18 minutes, or ≦20 minutes after the initiation of brain tissue injury (e.g., neuronal tissue injury). In a preferred embodiment, the neuroimmune response is enhanced ≦10 minutes after the initiation of brain tissue injury.

[0083] The term "brain tissue damage" (e.g., neuronal tissue damage) may refer to damage caused by a brain disorder described herein. For example, where the brain disorder is an infection, the brain tissue damage may be caused by a microbial infection.

[0084] In one embodiment, the neuroimmune response is enhanced <2 minutes, <4 minutes, <6 minutes, <8 minutes, <10 minutes, <12 minutes, <14 minutes, <16 minutes, <18 minutes, or <20 minutes after administration of the Clostridial neurotoxin. In a preferred embodiment, the neuroimmune response is enhanced <10 minutes after administration of the Clostridial neurotoxin.

[0085] The neuroimmune response may be enhanced for ≦48 hours, ≦36 hours, ≦24 hours, or ≦12 hours (preferably ≦24 hours) after the occurrence of brain tissue damage. For example, after the aforementioned period, the Clostridial neurotoxin-mediated enhancement of neuroimmunity may disappear; in other words, the Clostridial neurotoxin-mediated enhancement of neuroimmune response may disappear 48 hours, 36 hours, 24 hours, or 48 hours (preferably 24 hours) after the occurrence of brain tissue damage. In such embodiments, the Clostridial neurotoxin may be said to enhance an acute neuroimmune response. The term "no Clostridial neurotoxin-mediated enhancement" means that there is substantially no increase in the neuroimmune response. For example, "substantially no increase" preferably means that the increase in the neuroimmune response may be less than 5%, less than 3%, or less than 1% (preferably 0%, where there is no increase in the neuroimmune response at all).

[0086] As mentioned above, in this specification, brain disorders / brain damage are disorders that can be treated by promoting a neuroimmune response in a patient.

[0087] Such disorders may include disorders related to bodily injury that originate within or outside the brain and cause brain tissue damage. For example, in stroke, blood vessel blockage may interrupt or reduce the blood supply to the brain, leading to oxygen deprivation of the brain and therefore neuronal cell death. Therefore, the resulting neuronal damage may be behind the symptoms suffered by patients with the above-mentioned brain damage.

[0088] Therefore, the Clostridial neurotoxins of the present invention may be for treating brain disorders that cause brain tissue damage (eg, neuronal tissue damage), for example, by promoting a neuroimmune response.

[0089] Examples of brain disorders encompassed by the present invention include any one (or more) of traumatic brain injury, cancer (e.g., brain tumor), infectious disease, stroke, neurodegenerative disorder, cerebral aneurysm, multiple sclerosis, anoxic injury, toxic injury, and metabolic injury.

[0090] "Brain damage" may more specifically refer to brain tissue damage (e.g., neuronal tissue damage). In such cases, the brain damage may be said to be caused by any one (or more) of traumatic brain injury, cancer (e.g., brain tumor), infectious disease, stroke, neurodegenerative disorder, cerebral aneurysm, multiple sclerosis, anoxic injury, toxic injury, and metabolic injury.

[0091] In a preferred embodiment, the brain damage is caused by non-traumatic brain injury.Non-traumatic brain injury can be the result of disease, hypoxia, metabolic disorder, aneurysm, and / or cardiac arrest.Non-traumatic brain injury can be distinguished from "traumatic brain injury" (TBI), which is typically caused by a physical blow or impact to the head or a penetrating head injury that interrupts brain function.

[0092] In one embodiment, the brain damage is not caused by a "traumatic brain injury" (TBI).

[0093] Non-traumatic brain injury may be defined by one or more selected from the following: cancer (e.g., brain tumor), infectious disease, stroke, neurodegenerative disorder, cerebral aneurysm, multiple sclerosis, anoxic injury, toxic injury, and metabolic injury (preferably cancer, infectious disease, and stroke; more preferably infectious disease).

[0094] Preferred examples of brain damage in the present invention can be selected from brain damage caused by cancer, infectious disease, and stroke. In other words, the brain damage can be caused by cancer, infectious disease, and / or stroke.

[0095] A particularly preferred brain disorder is an infectious disease, in other words, the brain disorder can be caused by an infectious disease.

[0096] Infections can cause inflammation of the brain (encephalitis). Viruses are the most common cause of encephalitis. Infections can also cause inflammation of the layers of tissue that cover the brain (meninges). The resulting condition is called meningitis. Often, bacterial meningitis spreads to the brain itself, causing encephalitis. Similarly, viral infections that cause encephalitis often also cause meningitis. When both the brain and meninges are infected, the disorder is called meningoencephalitis. However, infections that primarily affect the meninges are usually called meningitis, and infections that primarily affect the brain are usually called encephalitis.

[0097] An infectious disease can refer to an infection by a microorganism, such as a microorganism selected from bacteria, viruses, fungi, parasites, and protozoa (more preferably selected from bacteria and fungi). Therefore, an infectious disease can be caused by an infectious agent containing nucleic acid (DNA, RNA, or both). This can be contrasted with the agent of prion protein infection. Therefore, an infectious disease can be distinguished from a prion disease.

[0098] In one embodiment, the infectious disease is selected from encephalitis, meningitis, and brain abscess (preferably encephalitis and meningitis). Thus, in one embodiment, the brain disorder may be encephalitis. In one embodiment, the brain disorder may be meningitis.

[0099] In one embodiment, the brain damage is caused by a neurodegenerative disease, which may be selected from Alzheimer's disease, Parkinson's disease, Parkinson's disease-related disorders, motor neuron diseases (e.g., amyotrophic lateral sclerosis), prion diseases, Huntington's disease, spinocerebellar ataxia, ataxia, Hallervorden-Spatz disease, and frontotemporal lobar degeneration.

[0100] In one embodiment, the brain damage is caused by a stroke, which can be an ischemic stroke (e.g., a lack of blood flow to the brain) or a hemorrhagic stroke (e.g., bleeding in the brain).

[0101] As used herein, a "patient" (which may be used interchangeably with the term "subject") may be a mammal, such as a human or other mammal. Preferably, "patient" refers to a human subject.

[0102] The patient may have a lower than average (basal) neuroimmune response, for example, a patient receiving an alternative treatment, such as chemotherapy, that may suppress the immune system. For example, the patient may be immunocompromised. The patient may be immunocompromised due to any underlying condition or due to an elderly condition (e.g., a patient >60 or 70 years old). Additionally or alternatively, the patient may be immunocompromised due to the administration of an alternative treatment (e.g., chemotherapy, as mentioned above). The latter represents a distinct subset of patients in whom an immunocompromised state is "induced," and such patients may particularly benefit from the treatments described herein.

[0103] As used herein, the term "disorder" also encompasses "disease." In one embodiment, a disorder is a disease.

[0104] As used herein, the term "treat" or "treating" encompasses preventative treatment (e.g., to prevent the occurrence of a disorder) and corrective treatment (treatment of a subject already suffering from a disorder). Preferably, as used herein, "treat" or "treating" refers to corrective treatment.

[0105] As used herein, the term "treat" or "treating" refers to a disorder and / or its symptoms.

[0106] Thus, the clostridial neurotoxins of the present invention can be administered to a patient in a therapeutically effective amount or a prophylactically effective amount. Preferably, the clostridial neurotoxins of the present invention are administered to a patient in a therapeutically effective amount.

[0107] A "therapeutically effective amount" is any amount of a Clostridial neurotoxin that, when administered alone or in combination with another agent to a patient for treating said disorder (or a symptom thereof), is sufficient to effect such treatment of the disorder or symptom thereof.

[0108] A "prophylactically effective amount" is any amount of a Clostridial neurotoxin that, when administered alone or in combination to a patient, inhibits or delays the onset or recurrence of a disorder (or symptoms thereof). In some embodiments, a prophylactically effective amount completely prevents the onset or recurrence of a disorder. "Inhibiting" onset means either reducing the likelihood of the onset of a disorder (or symptoms thereof) or preventing onset completely.

[0109] The Clostridial neurotoxin of the present invention can be formulated in any suitable manner for administration to a subject, for example, as part of a pharmaceutical composition. Thus, in one embodiment, the present invention provides a pharmaceutical composition for any of the methods of treatment described herein, the pharmaceutical composition comprising the Clostridial neurotoxin of the present invention and a pharmaceutically acceptable carrier, excipient, adjuvant, propellant, and / or salt.

[0110] In some embodiments, the clostridial neurotoxin of the present invention may be in a single-chain form, while in other embodiments, the clostridial neurotoxin may be in a two-chain form, for example, where the two chains are linked by a disulfide bridge.Preferably, the clostridial neurotoxin is in a two-chain form.

[0111] The clostridial neurotoxins of the present invention can be formulated for oral, parenteral, continuous infusion, inhalation, or topical application. Compositions suitable for injection can be in the form of a solution, suspension, or emulsion, or as a dry powder that is dissolved or suspended in a suitable base prior to use.

[0112] In the case of a clostridial neurotoxin to be delivered locally, the clostridial neurotoxin can be formulated as a cream (eg, for topical application) or for subdermal injection.

[0113] Local delivery means may include aerosols or other sprays (e.g., nebulizers), whereby aerosol formulations of Clostridial neurotoxins allow for delivery to the lungs and / or other nasal and / or bronchial or airway passages.

[0114] The clostridial neurotoxins of the present invention can be administered to a subject by intrathecal or epidural injection in the spinal column at the level of the spinal segment involved in innervating the affected organ.

[0115] The route of administration can be by local injection. In one embodiment, the clostridial neurotoxin of the present invention is administered at or near the site of injury, preferably at the site of injury. In one embodiment, the route of administration of the clostridial neurotoxin of the present invention can be perineuronal, intraneuronal, intraspinal, and / or intrathecal.

[0116] The clostridial neurotoxin can be administered subcutaneously and / or intracranially. For example, the clostridial neurotoxin can be administered intracranially (e.g., into any appropriate region of the brain where neuronal damage exists). For example, the clostridial neurotoxin can be administered by intracortical administration (e.g., intracortical injection). The clostridial neurotoxin can be administered to the somatosensory cortex. The clostridial neurotoxin can be administered to the frontal lobe.

[0117] Intracranial administration (eg, intracranial injection) can be used to allow for direct administration to the brain.

[0118] The dosage ranges for administration of the clostridial neurotoxins of the present invention are those to produce the desired therapeutic and / or prophylactic effect. It will be understood that the required dosage range will depend on the precise nature of the clostridial neurotoxin or composition, the route of administration, the nature of the formulation, the age of the subject, the nature, extent, or severity of the subject's condition, any contraindications, and the judgment of the attending physician. Variations in these dosage levels can be adjusted using standard empirical routines for optimization.

[0119] In one embodiment, the dose of the Clostridial neurotoxin is a flat dose. The flat dose can range from 50 pg to 250 μg, preferably from 100 pg to 100 μg. In one embodiment, the flat dose can be at least 50 pg, 100 pg, 500 pg, 1 ng, 50 ng, 100 ng, 500 ng, 1 μg, or 50 μg. The dose can be a single flat dose.

[0120] Fluid dosage forms are typically prepared using a clostridial neurotoxin and a pyrogen-free sterile base. Depending on the base and concentration used, the clostridial neurotoxin can either be dissolved or suspended in the base. In preparing a solution, the clostridial neurotoxin can be dissolved in the base. The solution is made isotonic by adding sodium chloride, if necessary, and sterilized by filtration through a sterile filter using aseptic techniques before filling and sealing into suitable sterile vials or ampoules. Alternatively, if the solution is sufficiently stable, the solution in the sealed container can be sterilized by autoclaving. Advantageously, additives such as buffers, solubilizers, stabilizers, preservatives or bactericides, suspending or emulsifying agents, and / or local anesthetics can be dissolved in the base.

[0121] Dry powders, which are dissolved or suspended in a suitable base prior to use, can be prepared by filling pre-sterilized ingredients into sterile containers using aseptic technique in a sterile area. Alternatively, the ingredients can be dissolved in suitable containers using aseptic technique in a sterile area. The product is then freeze-dried and the container is aseptically sealed.

[0122] Parenteral suspensions suitable for the routes of administration described herein are prepared in substantially the same manner, except that the sterile components are suspended in a sterile vehicle instead of being dissolved, and sterilization cannot be achieved by filtration. The components may be isolated in a sterile state, or alternatively, they may be sterilized after isolation, for example, by gamma irradiation.

[0123] Advantageously, a suspending agent, such as polyvinylpyrrolidone, is included in the composition(s) to facilitate uniform distribution of the components.

[0124] Administration according to the present invention may utilize a variety of delivery technologies, including microparticle encapsulation or high-pressure aerosol bombardment.

[0125] The Clostridial neurotoxin can be administered prior to, simultaneously with, or after the occurrence of brain tissue damage (e.g., neuronal tissue damage) caused by a brain disorder described herein. For example, where the brain disorder is caused by an infection, the Clostridial neurotoxin can be administered after the detection of the infection to promote clearance of the infection mediated by the neuroimmune response.

[0126] In one embodiment, the Clostridial neurotoxin can be administered prior to brain tissue damage (e.g., neuronal tissue damage). In other words, the Clostridial neurotoxin can be administered before brain tissue damage (e.g., neuronal tissue damage) occurs.

[0127] The phrase "administering a Clostridial neurotoxin before brain tissue damage (e.g., neuronal tissue damage) occurs" encompasses situations where brain tissue damage has occurred first. For example, a Clostridial neurotoxin can be administered to promote a neuroimmune response to treat or prevent further brain tissue damage. This is advantageous in the context of the brain disorders described herein, where (further) tissue damage may be expected.

[0128] In one embodiment, the Clostridial neurotoxin is administered up to four days before brain tissue damage (e.g., neuronal tissue damage). The Clostridial neurotoxin can be administered between one and three days before brain tissue damage (e.g., neuronal tissue damage) occurs. The Clostridial neurotoxin can be administered three days before brain tissue damage (e.g., neuronal tissue damage). In a preferred embodiment, the Clostridial neurotoxin can be administered ≦24 hours before brain tissue damage (e.g., neuronal tissue damage).

[0129] The present inventors have demonstrated that administration of a Clostridial neurotoxin can lead to a rapid promotion of a neuroimmune response. Therefore, a Clostridial neurotoxin can be administered when brain tissue damage has occurred and / or is occurring (or is suspected to have occurred and / or is occurring) to promote a neuroimmune response to respond to the damage.

[0130] In one embodiment, the clostridial neurotoxin is administered within 48 hours (e.g., less than or equal to 4 hours) after the onset of brain tissue (e.g., neuronal tissue) damage. For example, the clostridial neurotoxin can be administered ≦10 minutes, ≦30 minutes, ≦1 hour, ≦2 hours, ≦5 hours, ≦12 hours, ≦34 hours, ≦3 hours, or ≦48 hours after the onset of brain tissue damage (e.g., neuronal tissue damage). Preferably, the clostridial neurotoxin can be administered ≦2 hours after the onset of brain tissue damage (e.g., neuronal tissue damage). More preferably, the clostridial neurotoxin can be administered within 1 to 10 minutes after the onset of brain tissue damage (e.g., neuronal tissue damage).

[0131] As explained in more detail elsewhere in this disclosure, the term "clostridial neurotoxin" encompasses clostridial neurotoxin fragments thereof.

[0132] Further information about Clostridial neurotoxins and suitable neurotoxins for use in the present invention is now provided below.

[0133] In one embodiment, the present invention encompasses the use of a full-length clostridial neurotoxin comprising a clostridial neurotoxin L chain and a clostridial neurotoxin H chain, optionally with the proviso that the clostridial neurotoxin L chain is catalytically inactive.

[0134] The term "clostridial neurotoxin" encompasses toxins produced by C. botulinum (botulinum neurotoxin serotypes A, B, C1, D, E, F, G, and X), C. tetani (tetanus neurotoxin), C. butyricum (botulinum neurotoxin serotype E), and C. baratii (botulinum neurotoxin serotype F), as well as modified clostridial neurotoxins or derivatives derived from any of the foregoing.

[0135] Botulinum neurotoxins (BoNTs) are produced by C. botulinum in the form of large protein complexes consisting of BoNT itself complexed with several accessory proteins. Currently, there are eight different classes of botulinum neurotoxins: botulinum neurotoxin serotypes A, B, C1, D, E, F, G, and X, all of which share a similar structure and mode of action. Different BoNT serotypes can be distinguished based on inactivation by specific neutralizing antisera. This classification by serotype correlates with the percentage sequence identity at the amino acid level. Based on the percentage amino acid sequence identity, BoNT proteins of a given serotype can be further divided into different subtypes.

[0136] BoNTs are absorbed in the gastrointestinal tract and, after entering the systemic circulation, bind to the presynaptic membranes of cholinergic nerve terminals, preventing their release of the neurotransmitter acetylcholine. BoNT / B, BoNT / D, BoNT / F, and BoNT / G cleave synaptobrevin / vesicle-associated membrane protein (VAMP); BoNT / C1, BoNT / A, and BoNT / E cleave 25 kDa synaptosomal-associated protein (SNAP-25); BoNT / C1 cleaves syntaxin. BoNT / X has been found to cleave SNAP-25, VAMP1, VAMP2, VAMP3, VAMP4, VAMP5, Ykt6, and syntaxin 1.

[0137] Tetanus toxin is produced by C. tetani in a single serotype: C. butyricum produces BoNT / E, and C. baratii produces BoNT / F.

[0138] The term "clostridial neurotoxin" is intended to encompass both full-length neurotoxins (including clostridial neurotoxin L chains and clostridial neurotoxin H chains) and fragments thereof. For example, "clostridial neurotoxin" refers to a neurotoxin comprising a clostridial neurotoxin L chain, a clostridial neurotoxin translocation domain (H chain), a clostridial neurotoxin L chain, a clostridial neurotoxin H ... N ), and / or a Clostridial neurotoxin receptor binding domain (H CA "clostridial neurotoxin" may refer to a polypeptide comprising or consisting of a clostridial neurotoxin L chain, a clostridial neurotoxin translocation domain (H) domain. N ), and / or a Clostridial neurotoxin receptor binding domain (H C ) domain, and when the polypeptide comprises a Clostridial neurotoxin L chain, the L chain is catalytically inactive.

[0139] Advantageously, the use of clostridial neurotoxin fragments allows the use of non-toxic (or substantially non-toxic) fragments of clostridial neurotoxins, which, given their smaller size (compared to the full-length H chain or full-length clostridial neurotoxin), are less likely to provoke an adverse immune response (against the fragment) in a subject administered the fragment. Moreover, non-toxic (or substantially non-toxic) fragments are less expensive and / or less complicated to produce than full-length clostridial neurotoxins. In addition, non-toxic (or substantially non-toxic) fragments constitute more straightforward therapeutic agents than full-length clostridial toxins, and, given the shorter length of the polypeptide, there is a reduced probability of, for example, cysteine ​​shuffling between domains.

[0140] In embodiments that refer to a particular domain of a clostridial neurotoxin, the molecule may conveniently be referred to as a "polypeptide," i.e., the term "clostridial neurotoxin" may be substituted for the term "polypeptide."

[0141] Therefore, the clostridial neurotoxins referred to herein comprise a clostridial neurotoxin light chain (L chain), a clostridial neurotoxin translocation domain (H chain), ... N domain), and / or Clostridial neurotoxin receptor binding domain (H CThe clostridial neurotoxin referred to herein may refer to a polypeptide comprising (or consisting of) a clostridial neurotoxin light chain (L chain), a clostridial neurotoxin translocation domain (H chain), ... N domain), and / or Clostridial neurotoxin receptor binding domain (H C The term "catalytically inactive" may refer to a polypeptide comprising (or consisting of) a Clostridial neurotoxin L chain, and when the polypeptide comprises a Clostridial neurotoxin L chain, the L chain is catalytically inactive.

[0142] Thus, aspects of the present invention provide either: -Polypeptides for use in methods for treating brain disorders (e.g. by promoting a neuroimmune response); - a method of treating a brain disorder in a patient (e.g., by promoting a neuroimmune response), the method comprising administering a polypeptide to the patient; - use of a polypeptide in the manufacture of a medicament for treating a brain disorder in a patient (e.g. by promoting a neuroimmune response); The peptides include a clostridial neurotoxin light chain (L chain), a clostridial neurotoxin translocation domain (H chain), and a clostridial neurotoxin translocation domain (H chain). N domain), and / or Clostridial neurotoxin receptor binding domain (H C domain); optionally, when the polypeptide comprises a Clostridial neurotoxin L chain, the L chain is catalytically inactive.

[0143] In one embodiment, a clostridial neurotoxin of the present invention may be encoded by a nucleotide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, or 60. In one embodiment, a clostridial neurotoxin of the present invention may be encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, or 60. Preferably, the clostridial neurotoxin of the present invention may be encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, or 60.

[0144] In one embodiment, a clostridial neurotoxin of the present invention may comprise a clostridial neurotoxin sequence having at least 70% sequence identity to any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65. In one embodiment, a clostridial neurotoxin of the present invention may comprise a clostridial neurotoxin sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65. Preferably, the clostridial neurotoxin of the present invention may comprise any one of the clostridial neurotoxin sequences of SEQ ID NOs: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65.

[0145] In one embodiment, the clostridial neurotoxin of the present invention may comprise a clostridial neurotoxin sequence having at least 70% sequence identity to any one of SEQ ID NOs: 51, 52, 53, 54, 55, 56, 57, 58, or 59 (preferably SEQ ID NOs: 51, 52, 53, 54, 55, 56, 57, or 59). In one embodiment, the clostridial neurotoxin of the present invention may comprise a clostridial neurotoxin sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 51, 52, 53, 54, 55, 56, 57, 58, or 59 (preferably SEQ ID NOs: 51, 52, 53, 54, 55, 56, 57, or 59). Preferably, the clostridial neurotoxin of the present invention may comprise any one of the clostridial neurotoxin sequences of SEQ ID NO: 51, 52, 53, 54, 55, 56, 57, 58, or 59 (preferably SEQ ID NO: 51, 52, 53, 54, 55, 56, 57, or 59). In one embodiment, the clostridial neurotoxin of the present invention may comprise a clostridial neurotoxin sequence having at least 70% sequence identity to SEQ ID NO: 51. In one embodiment, the clostridial neurotoxin of the present invention may comprise a clostridial neurotoxin sequence having at least 80%, 90%, 95%, or 98% sequence identity to SEQ ID NO: 51. Preferably, the clostridial neurotoxin of the present invention may comprise the clostridial neurotoxin sequence of SEQ ID NO: 51.

[0146] The term "clostridial neurotoxin" is also intended to encompass modified clostridial neurotoxins and their derivatives, including, but not limited to, those described below. A modified clostridial neurotoxin or derivative may contain one or more amino acids that are modified compared to the native (unmodified) form of the clostridial neurotoxin, or may contain one or more inserted amino acids that are not present in the native (unmodified) form of the clostridial neurotoxin. For example, a modified clostridial neurotoxin may have an amino acid sequence in one or more domains that is modified relative to the native (unmodified) clostridial neurotoxin sequence. Such modifications may alter the functional aspects of the toxin, such as biological activity or persistence. Therefore, in one embodiment, the clostridial neurotoxin of the present invention is a modified clostridial neurotoxin, or a modified clostridial neurotoxin derivative, or a clostridial neurotoxin derivative.

[0147] The modified Clostridial neurotoxin may have a modified heavy chain amino acid sequence (e.g., a modified H C The modified heavy chain may have one or more modifications on the H domain, such that the modified heavy chain binds to target neurons with greater or less affinity than the native (unmodified) Clostridial neurotoxin. C Such modifications on the domain modulate binding to ganglioside receptors and / or protein receptors on target neurons. C This may involve modifying residues on the ganglioside binding site or on the protein (SV2 or synaptotagmin) binding site of the domain. Examples of such modified Clostridial neurotoxins are described in WO 2006 / 027207 and WO 2006 / 114308, both of which are incorporated herein by reference in their entirety.

[0148] The modified Clostridial neurotoxin may have one or more modifications in the amino acid sequence of the light chain, for example, modifications in the substrate binding or catalytic domain that may modulate or alter the SNARE protein specificity of the modified L chain. Examples of such modified Clostridial neurotoxins are described in WO 2010 / 120766 and US 2011 / 0318385, both of which are incorporated by reference in their entirety.

[0149] The modified clostridial neurotoxin may contain one or more modifications that increase or decrease the biological activity and / or biological persistence of the modified clostridial neurotoxin. For example, the modified clostridial neurotoxin may contain a leucine- or tyrosine-based motif, which increases or decreases the biological activity and / or biological persistence of the modified clostridial neurotoxin. Suitable leucine-based motifs include xDxxxLL, xExxxLL, xExxxIL, and xExxxLM (wherein x is any amino acid). Suitable tyrosine-based motifs include Yxx-Hy (wherein Hy is a hydrophobic amino acid). Examples of modified clostridial neurotoxins containing leucine- and tyrosine-based motifs are described in WO 2002 / 08268, which is incorporated herein by reference in its entirety.

[0150] As described above, the modified clostridial neurotoxin (or clostridial neurotoxin fragment) can comprise one or more modifications that increase the isoelectric point of the clostridial neurotoxin compared to an equivalent unmodified clostridial neurotoxin that lacks the one or more modifications.Suitable modified clostridial neurotoxins are described above and in WO 2015 / 004461 A1 and WO 2016 / 110662 A1, which are incorporated herein by reference.Exemplary sequences include SEQ ID NOs: 61 and 42 described herein.

[0151] The modified Clostridial neurotoxin may preferably comprise or consist of the sequence of SEQ ID NO:61.

[0152] The term "clostridial neurotoxin" is intended to encompass hybrid and chimeric clostridial neurotoxins. A hybrid clostridial neurotoxin comprises at least a portion of a light chain from one clostridial neurotoxin or subtype and at least a portion of a heavy chain from another clostridial neurotoxin or clostridial neurotoxin subtype. In one embodiment, a hybrid clostridial neurotoxin may contain the entire light chain from one clostridial neurotoxin subtype and a heavy chain from another clostridial neurotoxin subtype. In another embodiment, a chimeric clostridial neurotoxin contains a portion of the heavy chain (e.g., the binding domain) of one clostridial neurotoxin subtype, and another portion of the heavy chain may be from another clostridial neurotoxin subtype. Similarly or alternatively, a therapeutic element may comprise light chain portions from different clostridial neurotoxins. Such hybrid or chimeric clostridial neurotoxins are useful, for example, as a means of delivering the therapeutic benefits of such clostridial neurotoxins to subjects who are immunologically resistant to a given clostridial neurotoxin subtype, to subjects who may have a lower-than-average concentration of receptors for a given clostridial neurotoxin heavy chain binding domain, or to subjects who may have protease-resistant variants of membrane or vesicular toxin substrates (e.g., SNAP-25, VAMP, and syntaxin). Hybrid and chimeric clostridial neurotoxins are described in US 8,071,110, which is incorporated herein by reference in its entirety. Thus, in one embodiment, the clostridial neurotoxin (or fragment thereof) of the present invention is a hybrid clostridial neurotoxin or a chimeric clostridial neurotoxin.

[0153] In a particularly preferred embodiment, the polypeptide of the present invention comprises a BoNT / A light chain and translocation domain and a BoNT / B receptor binding domain (HC The neurotoxin may be a chimeric Clostridial neurotoxin comprising (preferably consisting of) the LH domain of BoNT / A or a portion thereof. N -BoNT / B H C ). Suitable chimeric and / or hybrid Clostridial neurotoxins may be those taught by WO 2017 / 191315 A1, which is incorporated herein by reference. Such preferred sequences include SEQ ID NOs: 44, 63, and 64.

[0154] For example, a chimeric Clostridial neurotoxin may comprise (and preferably consist of) the sequence of SEQ ID NO: 64, which may be said to comprise a catalytically inactive L chain.

[0155] In a preferred embodiment, the chimeric Clostridial neurotoxin may comprise (preferably consist of) the sequence of SEQ ID NO:63.

[0156] BoNT / A LH N The domain is BoNT / B H C The chimeric BoNT / A may be covalently linked to the domain. Such chimeric BoNT / A is also referred to herein as a "BoNT / AB" or a "BoNT / AB chimera."

[0157] LH N The C-terminal amino acid residue of the domain is the LH of BoNT / A. N and H C Separating Domains 3 10 It may correspond to the first amino acid residue of the helix. C The N-terminal amino acid residue of the domain is the LH of BoNT / B. N and H C Separating Domains 3 10 It may correspond to the second amino acid residue of the helix.

[0158] As used herein, "BoNT / A LH N and H C Separating Domains 3 10 The first amino acid residue of the helix is ​​the LHN and H C Separating Domains 3 10 It refers to the N-terminal residue of the helix.

[0159] As used herein, "BoNT / B LH N and H C Separating Domains 3 10 The second amino acid residue of the helix is N and H C Separating Domains 3 10 It refers to the amino acid residues following the N-terminal residue of the helix.

[0160] "3 10 A "helix" is a type of secondary structure found on proteins and polypeptides, along with alpha helices, beta sheets, and reverse turns. 3 10 The amino acids on the helix are arranged in a right-handed helix, where each turn is completed by three residues and ten atoms separating the intermolecular hydrogen bonds between them. Each amino acid has ten atoms in a ring formed by making hydrogen bonds, corresponding to a 120° turn on the helix (i.e., the helix has three residues per turn) and a 2.0 Å (=0.2 nm) translation along the helix axis. Most importantly, the NH group of an amino acid forms a hydrogen bond with the C=O group of the amino acid three residues before it; this repeating i+3→i hydrogen bond completes three cycles. 10 Define a helix. 3 10 Helices are a standard concept in structural biology and are familiar to those skilled in the art.

[0161] These three 10 A helix corresponds to the four residues that form the actual helix plus two cap (or connecting) residues, one on each end of these four residues. N and H C Separating Domains 3 10 The "helix" consists of these six residues.

[0162] By performing structural analysis and sequence alignment, LH N and H C Separating Domains 3 10 The three helices were identified. 10 The helix is ​​located at its N-terminus (i.e., LH N at the C-terminal end of the domain) by an α-helix, and at its C-terminus (i.e., H C At the N-terminal end of the domain, it is surrounded by β-strands. 10 The first (N-terminal) residue of the helix (the cap or connecting residue) also corresponds to the C-terminal residue of this α-helix.

[0163] LH N and H C Separating Domains 3 10 The helices can be determined for botulinum neurotoxins A1 and B1, for example, from publicly available crystal structures of botulinum neurotoxins, such as 3BTA (http: / / www.rcsb.org / pdb / explore / explore.do?structureId=3BTA) and 1EPW (http: / / www.rcsb.org / pdb / explore / explore.do?structureId=1EPW), respectively.

[0164] Publicly available in silico modeling and alignment tools also support the identification of LH on other neurotoxins. N and H C Separating Domains 3 10It can be used to determine the orientation of the helices. Examples include the homology modeling servers LOOPP (Learning, Observing and Outputting Protein Patterns, http: / / loopp.org), PHYRE (Protein homology / analogY Recognition Engine, http: / / www.sbg.bio.ic.ac.uk / phyre2 / ), and Rosetta (https: / / www.rosettacommons.org / ), the protein superposition server SuperPose (http: / / wishart.biology.ualberta.ca / superpose / ), the alignment program Clustal Omega (http: / / www.clustal.org / omega / ), and several other tools / services listed in Internet Resources for Molecular and Cell Biologists (http: / / molbiol-tools.ca / ). In particular, the "H N / H CN The region around the junction is highly structurally conserved, making it an ideal region for overlapping different serotypes.

[0165] For example, the following methodology demonstrates the effectiveness of this 3-fold increase over other neurotoxins: 10 can be used to determine the sequence of the helix: 1. The structural homology modeling tool LOOP ( http: / / loopp.org ) was used to obtain predicted structures of other BoNT serotypes based on the BoNT / A1 crystal structure ( 3BTA.pdb ); 2.The resulting structure (pdb) file is H CN The N-terminal end of the domain and approximately 80 residues before it (these are H NIt encompasses only the structurally highly conserved "H" domain. N / H CN ” edited to preserve the area; 3. The protein superposition server SuperPose ( http: / / wishart.biology.ualberta.ca / superpose / ) was used to superimpose each serotype onto the 3BTA.pdb structure; 4. The overlapping pdb files are the H of BoNT / A1. C First 3 of the domain 10 The helices were scanned to locate them, and then corresponding residues in other serotypes were identified; 5. Other BoNT serotype sequences were aligned by Clustal Omega to check that corresponding residues were correct.

[0166] LH determined by this method N , H C , and 3 10 An example of a helical domain is provided below: [Table 1]

[0167] Using structural analysis and sequence alignment, LH N and H C Separating Domains 3 10 The β-strand following the helix is ​​a conserved structure in all botulinum and tetanus neurotoxins, and is the LH N and H C Separating Domains 3 10 It was found that when starting from the first residue of the helix, it begins at the eighth residue (eg, at residue 879 for BoNT / A1).

[0168] BoNT / AB chimera is a chimera derived from BoNT / B. C LH from BoNT / A covalently linked to the domain N domain, LH N The C-terminal amino acid residue of the domain is H of BoNT / A. C corresponds to the eighth amino acid residue at the N-terminus of the β-strand located at the beginning (N-terminus) of the domain, H C The N-terminal amino acid residue of the domain is the H C It corresponds to the seventh amino acid residue at the N-terminus of the β-strand located at the beginning (N-terminus) of the domain.

[0169] BoNT / AB chimera is a chimera derived from BoNT / B. C LH from BoNT / A covalently linked to the domain N domain, LH N The C-terminal amino acid residue of the domain is the LH of BoNT / A. N corresponds to the C-terminal amino acid residue of the α-helix located at the end (C-terminus) of the domain, H C The N-terminal amino acid residue of the domain is the LH of BoNT / B. N It corresponds to the amino acid residue immediately C-terminal to the C-terminal amino acid residue of the α-helix located at the end (C-terminus) of the domain.

[0170] The rationale for the design process of the BoNT / AB chimera was to strive to ensure that the secondary structure was not disrupted, thereby minimizing any changes in the tertiary structure and function of each domain. Without wishing to be bound by theory, the three 10 It is hypothesized that not blocking the four central amino acid residues of the helix ensures an optimal conformation for the chimeric neurotoxins, thereby allowing the chimeric neurotoxins to exert their function to their fullest extent.

[0171] LH from BoNT / A NThe domain may correspond to amino acid residues 1 to 872 of SEQ ID NO: 62, or a polypeptide sequence having at least 70% sequence identity thereto. N The domain may correspond to amino acid residues 1 to 872 of SEQ ID NO: 62, or a polypeptide sequence having at least 80%, 90%, or 95% sequence identity thereto. Preferably, the LH domain from BoNT / A N The domain corresponds to amino acid residues 1 to 872 of SEQ ID NO:62.

[0172] H from BoNT / B C The domain may correspond to amino acid residues 860 to 1291 of SEQ ID NO: 52, or a polypeptide sequence having at least 70% sequence identity thereto. C The domain can correspond to amino acid residues 860 to 1291 of SEQ ID NO: 52, or a polypeptide sequence having at least 80%, 90%, or 95% sequence identity thereto. Preferably, the H domain from BoNT / B C The domain corresponds to amino acid residues 860 to 1291 of SEQ ID NO:52.

[0173] Preferably, the BoNT / AB chimera is a BoNT / A LH N Domain and H of BoNT / B C More preferably, the LH domain N The domain corresponds to amino acid residues 1 to 872 of BoNT / A (SEQ ID NO: 62), and C The domain corresponds to amino acid residues 860 to 1291 of BoNT / B (SEQ ID NO: 52).

[0174] Preferably, H of BoNT / B C The domain further comprises at least one amino acid residue substitution, addition, or deletion. CC The BoNT / B neurotoxin contains a subdomain of the nucleotide sequence H, which has the effect of increasing the binding affinity of the BoNT / B neurotoxin to human Syt II compared to the native BoNT / B sequence. CCSuitable amino acid residue substitutions, additions, or deletions on the subdomains are disclosed in WO 2013 / 180799 and WO 2016 / 154534 (both of which are incorporated herein by reference).

[0175] BoNT / B H CC Suitable amino acid residue substitutions, additions, or deletions on the subdomains include substitution mutations selected from the group consisting of: V1118M; Y1183M; E1191M; E1191I; E1191Q; E1191T; S1199Y; S1199F; S1199L; S1201V; E1191C, E1191V, E1191L, E1191Y, S1199W, S1199E, S1199H, W1178Y, W1178Q, W1178A, W1178S, Y1183C, Y1183P, and combinations thereof.

[0176] BoNT / B H CC Suitable amino acid residue substitutions, additions, or deletions on the subdomains further include combinations of two substitution mutations selected from the group consisting of: E1191M and S1199L, E1191M and S1199Y, E1191M and S1199F, E1191Q and S1199L, E1191Q and S1199Y, E1191Q and S1199F, E1191M and S1199W, E1191M and W1178Q, E1191C and S1199W, E1191C and S1199Y, E1191C and W1178Q, E1191Q and S1199W, E1191V and S1199W, E1191V and S1199Y, or E1191V and W1178Q.

[0177] BoNT / B H CC Suitable amino acid residue substitutions, additions, or deletions on the subdomains also include the combination of the three substitution mutations: E1191M, S1199W, and W1178Q.

[0178] Preferably, H of BoNT / B CCA preferred amino acid residue substitution, addition, or deletion on the subdomain includes the combination of two substitution mutations: E1191M and S1199Y.

[0179] The alterations may be alterations relative to unaltered BoNT / B, set forth as SEQ ID NO:52. Amino acid residue numbering is determined by alignment with SEQ ID NO:52. Because the presence of a methionine residue at position 1 of SEQ ID NO:52 is optional, one of skill in the art would take the presence / absence of the methionine residue into account when determining the amino acid residue numbering. For example, where SEQ ID NO:52 includes a methionine, the position numbering would be as defined above (e.g., E1191 would be E1191 in SEQ ID NO:52). Alternatively, where a methionine is absent from SEQ ID NO:52, the amino acid residue numbering should be altered by -1 (e.g., E1191 would be E1190 in SEQ ID NO:52). Similar considerations apply when a methionine is present / absent at position 1 of the other polypeptide sequences described herein, and one of skill in the art would have no difficulty determining the correct amino acid residue numbering using techniques routine in the art.

[0180] Therefore, in one embodiment, the present invention provides a Clostridial neurotoxin for use in treating a brain disorder by promoting a neuroimmune response in a subject, wherein the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63 or 64 (preferably, the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63).

[0181] In a related embodiment, a method is provided for treating a brain disorder in a subject by promoting neuroimmune activity, the method comprising administering a Clostridial neurotoxin to the subject, wherein the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63 or 64 (preferably, the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63).

[0182] In a further related embodiment, there is provided the use of a Clostridial neurotoxin in the manufacture of a medicament for treating a brain disorder in a subject by promoting a neuroimmune response, wherein the Clostridial neurotoxin comprises a Clostridial neurotoxin sequence having at least 70% sequence identity to SEQ ID NO: 63 or 64 (preferably, the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63).

[0183] In one embodiment, the present invention provides a Clostridial neurotoxin for use in treating a brain disorder in a subject, wherein the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63 or 64 (preferably, the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63).

[0184] In a related embodiment, a method is provided for treating a brain disorder in a subject, the method comprising administering a Clostridial neurotoxin to the subject, wherein the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63 or 64 (preferably, the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63).

[0185] In a further related embodiment, there is provided the use of a Clostridial neurotoxin in the manufacture of a medicament for treating a brain disorder in a subject, wherein the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63 or 64 (preferably, the Clostridial neurotoxin comprises a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 63).

[0186] In one embodiment, a clostridial neurotoxin for use in accordance with the present invention comprises a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to SEQ ID NO: 63 or 64. Preferably, a clostridial neurotoxin for use in accordance with the present invention comprises (more preferably consists of) the polypeptide sequence set forth as SEQ ID NO: 63 or 64.

[0187] For example, a Clostridial neurotoxin for use in accordance with the present invention may comprise a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to SEQ ID NO: 64. A Clostridial neurotoxin may comprise (more preferably consist of) the polypeptide sequence set forth as SEQ ID NO: 64.

[0188] In preferred embodiments, a clostridial neurotoxin for use in accordance with the present invention may comprise a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to SEQ ID NO: 64. For example, a particularly suitable clostridial neurotoxin may comprise (or more preferably consist of) the polypeptide sequence set forth as SEQ ID NO: 63.

[0189] Preferably, a clostridial neurotoxin comprising a polypeptide sequence having at least 70% sequence identity to SEQ ID NO:63 comprises a catalytically inactive L chain, eg, SEQ ID NO:64.

[0190] Chimeric and / or hybrid Clostridial neurotoxins for use in the present invention can contain some portion of a BoNT / A polypeptide and some portion of a BoNT / B polypeptide. Examples of this include the polypeptide set forth herein as SEQ ID NO:44.

[0191] A suitable chimeric clostridial neurotoxin can include BoNT / FA. Indeed, in particularly preferred embodiments, a clostridial neurotoxin (e.g., a chimeric clostridial neurotoxin) of the present invention can include BoNT / FA or a fragment thereof. Catalytically inactive forms of BoNT / FA are set forth herein as SEQ ID NOs: 26 and 34. Suitable fragments of BoNT / FA are also set forth herein as SEQ ID NOs: 28, 30, and 32.

[0192] The term "clostridial neurotoxin" also encompasses newly discovered members of the botulinum neurotoxin protein family expressed by non-clostridial microorganisms, such as the toxin encoded by Enterococcus spp., which shares closest sequence identity with BoNT / X, the toxin encoded by Weissella oryzae called BoNT / Wo (NCBI RefSeq: WP_027699549.1) that cleaves VAMP2 at W89-W90, the toxin encoded by Enterococcus faecium (GenBank: OTO22244.1) that cleaves VAMP2 and SNAP25, and the toxin encoded by Chryseobacterium pipero (NCBI Ref.Seq: WP_034687872.1).

[0193] The clostridial neurotoxins of the present invention are functional H C It may lack any functionally equivalent exogenous ligand targeting moiety (TM).

[0194] Therefore, in a particularly preferred embodiment, the clostridial neurotoxin of the present invention is not a retargeted clostridial neurotoxin. In a retargeted clostridial neurotoxin, the clostridial neurotoxin is modified to include an exogenous ligand known as a targeting moiety (TM). The TM is selected to provide binding specificity for the desired target cell, and as part of the retargeting process, the native binding moiety of the clostridial neurotoxin (e.g., H C Domain or H CCdomain) may be removed. Retargeting technologies are described, for example, in: EP-B-0689459; WO 1994 / 021300; EP-B-0939818; US 6,461,617; US 7,192,596; WO 1998 / 007864; EP-B-0826051; US ​​5,989,545; US 6,395,513; US 6,962,703; WO 1996 / 033273; EP-B-0996468; US 7,052,702; WO 1999 / 017806; EP-B-1107794; US 6,632,440; WO 2000 / 010598; WO 2001 / 21213; WO 2006 / 059093; WO 2000 / 62814; WO 2000 / 04926; WO 1993 / 15766; WO 2000 / 61192; and WO 1999 / 58571; all of which are incorporated herein by reference in their entireties.

[0195] As discussed above, (full-length) clostridial neurotoxins are formed from two polypeptide chains, a heavy chain (H chain) with a molecular mass of approximately 100 kDa and a light chain (L chain) with a molecular mass of approximately 50 kDa. The H chain contains a C-terminal targeting component (receptor binding domain or H C domain) and the N-terminal translocation component (H N domain).

[0196] The clostridial neurotoxin may be selected from BoNT / A, BoNT / B, BoNT / C, BoNT / D, BoNT / E, BoNT / F, BoNT / G, BoNT / X, and TeNT (tetanus neurotoxin). Preferably, the clostridial neurotoxin is a botulinum neurotoxin, such as a botulinum neurotoxin selected from BoNT / A, BoNT / B, BoNT / C, BoNT / D, BoNT / E, BoNT / F, BoNT / G, and BoNT / X.

[0197] In one embodiment, the clostridial neurotoxin can be BoNT / A. The reference BoNT / A sequence is set forth as SEQ ID NO: 51. In another embodiment, the clostridial neurotoxin can be BoNT / B. The reference BoNT / B sequence is set forth as SEQ ID NO: 52. In another embodiment, the clostridial neurotoxin can be BoNT / C. The reference BoNT / C sequence is set forth as SEQ ID NO: 53. In another embodiment, the clostridial neurotoxin can be BoNT / D. The reference BoNT / D sequence is set forth as SEQ ID NO: 54. In another embodiment, the clostridial neurotoxin can be BoNT / E. The reference BoNT / E sequence is set forth as SEQ ID NO: 55. In another embodiment, the clostridial neurotoxin can be BoNT / F. The reference BoNT / F sequence is set forth as SEQ ID NO: 56. In another embodiment, the clostridial neurotoxin can be BoNT / G. The reference BoNT / G sequence is set forth as SEQ ID NO: 57. In another embodiment, the clostridial neurotoxin can be TeNT. The reference TeNT sequence is set forth as SEQ ID NO: 58. In another embodiment, the Clostridial neurotoxin can be BoNT / X. A reference BoNT / X sequence is provided as SEQ ID NO:59.

[0198] In one embodiment, a clostridial neurotoxin of the present invention comprises a fragment of BoNT / A or a fragment of BoNT / F. In another embodiment, a clostridial neurotoxin of the present invention comprises a catalytically inactive L chain of BoNT / A or BoNT / F. For example, a clostridial neurotoxin of the present invention can comprise a catalytically inactive L chain of BoNT / A.

[0199] In embodiments in which the clostridial neurotoxins described herein have a tag (eg, a His tag) and / or a linker for purification, the tag and / or linker are optional.

[0200] Suitable full-length Clostridial neurotoxins are described herein.

[0201] In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65. However, preferably, the clostridial neurotoxin L chain of the clostridial neurotoxin is catalytically inactive. In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65. However, preferably, the Clostridial neurotoxin L chain of the Clostridial neurotoxin is catalytically inactive. Preferably, the Clostridial neurotoxin of the present invention may comprise a polypeptide sequence comprising any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65. However, preferably, the Clostridial neurotoxin L chain of the Clostridial neurotoxin is catalytically inactive.

[0202] In one embodiment, the clostridial neurotoxin of the present invention may be encoded by a nucleotide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 1, 9, 11, 13, 15, 17, 25, 33, or 60, provided that the clostridial neurotoxin L chain of the clostridial neurotoxin is preferably catalytically inactive. In one embodiment, the clostridial neurotoxin of the present invention may be encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 1, 9, 11, 13, 15, 17, 25, 33, or 60, provided that the clostridial neurotoxin L chain of the clostridial neurotoxin is preferably catalytically inactive. Preferably, the clostridial neurotoxin of the present invention is encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 1, 9, 11, 13, 15, 17, 25, 33, or 60, provided that preferably, the clostridial neurotoxin L chain of said clostridial neurotoxin is catalytically inactive.

[0203] In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 64, or 65, provided that the clostridial neurotoxin L chain of the clostridial neurotoxin is preferably catalytically inactive. In one embodiment, the clostridial neurotoxin of the present invention comprises a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 64, or 65, provided that the clostridial neurotoxin L chain of the clostridial neurotoxin is preferably catalytically inactive. Preferably, the clostridial neurotoxin of the present invention comprises any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 64, or 65, provided that preferably the clostridial neurotoxin L chain of said clostridial neurotoxin is catalytically inactive.

[0204] In one embodiment, the clostridial neurotoxin of the present invention is a full-length clostridial neurotoxin selected from BoNT / A, BoNT / B, BoNT / C, BoNT / D, BoNT / E, BoNT / F, BoNT / G, BoNT / X, and TeNT.

[0205] In one embodiment, the clostridial neurotoxin of the present invention is a full-length clostridial neurotoxin selected from BoNT / B, BoNT / C, BoNT / D, BoNT / E, BoNT / F, BoNT / G, BoNT / X, and TeNT.

[0206] In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 51-59, 61, or 63. In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 51-59, 61, or 63. In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 99% or 99.9% sequence identity to any one of SEQ ID NOs: 51-59, 61, or 63. Preferably, the clostridial neurotoxin of the present invention may comprise (more preferably consist of) a polypeptide sequence comprising any one of SEQ ID NOs: 51-59, 61, or 63.

[0207] In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 52 to 59, 61, or 63. In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 52 to 59, 61, or 63. In one embodiment, the clostridial neurotoxin of the present invention may comprise a polypeptide sequence having at least 99% or 99.9% sequence identity to any one of SEQ ID NOs: 52 to 59, 61, or 63. Preferably, the clostridial neurotoxin of the present invention may comprise (more preferably consist of) a polypeptide sequence comprising any one of SEQ ID NOs: 52 to 59, 61, or 63.

[0208] In one embodiment, the clostridial neurotoxin of the invention is not a full-length catalytically active clostridial neurotoxin, eg, is not a full-length catalytically active BoNT / A.

[0209] A clostridial neurotoxin of the present invention may comprise (or consist of) a fragment of a clostridial neurotoxin, for example, a fragment of any full-length clostridial neurotoxin described herein.

[0210] In one embodiment, a clostridial neurotoxin of the present invention may comprise a fragment of a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65. In one embodiment, a clostridial neurotoxin of the present invention may comprise a fragment of a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65. Preferably, a Clostridial neurotoxin of the present invention may comprise a fragment of a polypeptide sequence comprising any one of SEQ ID NOs: 2, 10, 12, 14, 16, 18, 26, 34, 51, 52, 53, 54, 55, 56, 57, 58, 59, 61, 62, 63, 64, or 65.

[0211] In one embodiment, the clostridial neurotoxin of the present invention comprises (or consists of) a clostridial neurotoxin L chain or a fragment thereof. The fragment of the clostridial neurotoxin L chain may have ≦400, ≦350, ≦300, ≦250, ≦200, ≦150, ≦100, or ≦50 amino acid residues of the clostridial neurotoxin L chain. In one embodiment, the fragment of the clostridial neurotoxin L chain has at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, or 200 amino acid residues of the clostridial neurotoxin L chain. For example, the fragment of the clostridial neurotoxin L chain may have 20 to 400, 50 to 300, or 100 to 200 amino acid residues of the clostridial neurotoxin L chain.

[0212] Examples of light chain reference sequences include: Botulinum type A neurotoxin: amino acid residues 1-448 Botulinum type B neurotoxin: amino acid residues 1-440 Botulinum type C1 neurotoxin: amino acid residues 1-441 Botulinum type D neurotoxin: amino acid residues 1-445 Botulinum type E neurotoxin: amino acid residues 1-422 Botulinum type F neurotoxin: amino acid residues 1-439 Botulinum type G neurotoxin: amino acid residues 1-441 Tetanus neurotoxin: amino acid residues 1-457

[0213] In the recently identified BoNT / X, the light chain is reported to correspond to amino acids 1-439, with the boundaries of the light chain potentially varying by approximately 25 amino acids (e.g., 1-414 or 1-464).

[0214] The reference sequences identified above should be considered as a guide, as minor variations may occur according to serosubtype. As an example, US 2007 / 0166332 (hereby incorporated by reference in its entirety) cites minor different Clostridial sequences: Botulinum type A neurotoxin: amino acid residues M1-K448 Botulinum type B neurotoxin: amino acid residues M1-K441 Botulinum type C1 neurotoxin: amino acid residues M1-K449 Botulinum type D neurotoxin: amino acid residue M1-R445 Botulinum type E neurotoxin: amino acid residue M1-R422 Botulinum type F neurotoxin: amino acid residues M1-K439 Botulinum type G neurotoxin: amino acid residues M1-K446 Tetanus neurotoxin: amino acid residues M1-A457

[0215] Suitable clostridial neurotoxin light chains are described herein.

[0216] The clostridial neurotoxin L chain may comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 6, 24, 32, or 40, or a fragment thereof. In one embodiment, the clostridial neurotoxin L chain comprises a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 6, 24, 32, or 40, or a fragment thereof. Preferably, the clostridial neurotoxin L chain comprises (more preferably consists of) a polypeptide sequence comprising any one of SEQ ID NOs: 6, 24, 32, or 40, or a fragment thereof.

[0217] The clostridial neurotoxin L chain can be encoded by a nucleotide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 5, 23, 31, or 39, or a fragment thereof. In one embodiment, the clostridial neurotoxin L chain is encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 5, 23, 31, or 39, or a fragment thereof. Preferably, the clostridial neurotoxin L chain is encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 5, 23, 31, or 39, or a fragment thereof.

[0218] In one embodiment, the clostridial neurotoxin of the present invention comprises (or consists of) a fragment of a clostridial neurotoxin H chain. The fragment of a clostridial neurotoxin H chain may have ≦800, ≦700, ≦600, ≦500, ≦400, ≦350, ≦300, ≦250, ≦200, ≦150, ≦100, or ≦50 amino acid residues of the clostridial neurotoxin H chain. In one embodiment, the fragment of a clostridial neurotoxin H chain has at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, or 200 amino acid residues of the clostridial neurotoxin H chain. For example, the fragment of a clostridial neurotoxin H chain may have 20 to 800, 30 to 600, 40 to 400, 50 to 300, or 100 to 200 amino acid residues of the clostridial neurotoxin H chain.

[0219] The heavy chains of clostridial neurotoxins contain two structural / functional domains: the translocation domain (H N ) and receptor binding domain (H C ) is included.

[0220] In one embodiment, the clostridial neurotoxin of the present invention comprises (or consists of) a clostridial neurotoxin translocation domain or a fragment thereof. A fragment of a clostridial neurotoxin translocation domain can have ≦400, ≦350, ≦300, ≦250, ≦200, ≦150, ≦100, or ≦50 amino acid residues of the clostridial neurotoxin translocation domain. In one embodiment, a fragment of a clostridial neurotoxin translocation domain has at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, or 200 amino acid residues of the clostridial neurotoxin translocation domain. For example, a fragment of a clostridial neurotoxin translocation domain can have 20 to 400, 50 to 300, or 100 to 200 amino acid residues of the clostridial neurotoxin translocation domain.

[0221] The translocation domain is a fragment of the H chain of a clostridial neurotoxin approximately equivalent to the amino-terminal half of the H chain, or a domain corresponding to that fragment on an intact H chain. C The function is H C It can be removed by deletion of the amino acid sequence (either at the level of DNA synthesis or at the post-synthetic level, by nuclease or protease treatment). C The function can be inactivated by chemical or biological treatment, and therefore, in some embodiments, the heavy chain may be unable to bind to the binding site on the target cell to which the native Clostridial neurotoxin (i.e., holotoxin) binds.

[0222] Examples of suitable (reference) translocation domains include: Botulinum type A neurotoxin - amino acid residues (449-871) Botulinum type B neurotoxin - amino acid residues (441-858) Botulinum type C neurotoxin - amino acid residues (442-866) Botulinum type D neurotoxin - amino acid residues (446-862) Botulinum type E neurotoxin - amino acid residues (423-845) Botulinum type F neurotoxin - amino acid residues (440-864) Botulinum type G neurotoxin - amino acid residues (442-863) Tetanus neurotoxin - amino acid residues (458-879)

[0223] The reference sequences identified above should be considered as a guide, as minor variations may occur according to serosubtype. As an example, US 2007 / 0166332 (incorporated herein by reference) cites slightly different Clostridial sequences: Botulinum type A neurotoxin - amino acid residues (A449-K871) Botulinum type B neurotoxin - amino acid residues (A442-S858) Botulinum type C neurotoxin - amino acid residues (T450-N866) Botulinum type D neurotoxin - amino acid residues (D446-N862) Botulinum type E neurotoxin - amino acid residues (K423-K845) Botulinum type F neurotoxin - amino acid residues (A440-K864) Botulinum type G neurotoxin - amino acid residues (S447-S863) Tetanus neurotoxin - amino acid residues (S458-V879)

[0224] In the context of the present invention, various clostridial neurotoxins H containing a translocation domain N In one embodiment, these active fragments facilitate the release of non-cytotoxic proteases (e.g., clostridial L chains) from intracellular vesicles into the cytoplasm of target cells, and may therefore be involved in the clostridial neurotoxin exerting its overall cellular mechanism of proteolytic cleavage of substrates. N The region is approximately 410-430 amino acids in length and contains the translocation domain. N This demonstrates that the entire length of the translocation domain is not required for translocation activity. Thus, aspects of this embodiment include Clostridial neurotoxin H containing a translocation domain having a length of, for example, at least 350 amino acids, at least 375 amino acids, at least 400 amino acids, or at least 425 amino acids. N Other aspects of this embodiment include a Clostridial neurotoxin H that includes a translocation domain having a length of, for example, at most 350 amino acids, at most 375 amino acids, at most 400 amino acids, or at most 425 amino acids. N It may include a region.

[0225] For further details on the genetic basis of toxin production in Clostridium botulinum and C. tetani, see Henderson et al (1997), The Clostridia: Molecular Biology and Pathogenesis, Academic Press.

[0226] Term H N is a naturally occurring neurotoxin H N portions, and modified H having non-naturally occurring amino acid sequences and / or synthetic amino acid residues. N In one embodiment, the modified H N The moiety still demonstrates the transition function mentioned above.

[0227] In a preferred embodiment, the clostridial neurotoxin of the present invention comprises a clostridial neurotoxin receptor binding domain (H C ) or a fragment thereof. C ) fragments of the Clostridial neurotoxin receptor binding domain (H C In one embodiment, the clostridial neurotoxin receptor binding domain (H) may have ≦350, ≦300, ≦250, ≦200, ≦150, ≦100, or ≦50 amino acid residues. C ) fragments of the Clostridial neurotoxin receptor binding domain (H C ), at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 150, or 200 amino acid residues of a Clostridial neurotoxin receptor binding domain (H C ) fragments of the Clostridial neurotoxin receptor binding domain (H C ) may have 20 to 350, 50 to 300, or 100 to 200 amino acid residues.

[0228] Clostridial neurotoxin receptor binding domain (H C ) Examples of reference sequences include: BoNT / A - N872-L1296 BoNT / B - E859-E1291 BoNT / C1 - N867-E1291 BoNT / D - S863-E1276 BoNT / E - R846-K1252 BoNT / F - K865-E1274 BoNT / G - N864-E1297 TeNT - I880-D1315

[0229] In the recently identified BoNT / X, H C The domain is reported to correspond to amino acids 893-1306, with the domain boundaries potentially varying by approximately 25 amino acids (e.g., 868-1306 or 918-1306).

[0230] The clostridial neurotoxin heavy chain may further comprise a translocation-facilitating domain, which facilitates delivery of the light chain into the cytosol of a target cell, and is described, for example, in WO 08 / 008803 and WO 08 / 008805, each of which is incorporated herein by reference.

[0231] For example, the translocation-facilitating domain is a clostridial neurotoxin H CN The neurotoxin may comprise a domain or a fragment or variant thereof. More particularly, the neurotoxin may comprise a clostridial neurotoxin H CN The translocation-facilitating domain may have a length of at least 200 amino acids, at least 225 amino acids, at least 250 amino acids, or at least 275 amino acids. CN The translocation-facilitating domain preferably has a length of at most 200 amino acids, at most 225 amino acids, at most 250 amino acids, or at most 275 amino acids. Specific (reference) examples include: Botulinum type A neurotoxin - amino acid residues (872-1110) Botulinum type B neurotoxin - amino acid residues (859-1097) Botulinum type C neurotoxin - amino acid residues (867-1111) Botulinum type D neurotoxin - amino acid residues (863-1098) Botulinum type E neurotoxin - amino acid residues (846-1085) Botulinum type F neurotoxin - amino acid residues (865-1105) Botulinum type G neurotoxin - amino acid residues (864-1105) Tetanus neurotoxin - amino acid residues (880-1127)

[0232] The above sequence positions may vary slightly depending on the serotype / subtype. CN Further examples of domains include: Botulinum type A neurotoxin - amino acid residues (874-1110) Botulinum type B neurotoxin - amino acid residues (861-1097) Botulinum type C neurotoxin - amino acid residues (869-1111) Botulinum type D neurotoxin - amino acid residues (865-1098) Botulinum type E neurotoxin - amino acid residues (848-1085) Botulinum type F neurotoxin - amino acid residues (867-1105) Botulinum type G neurotoxin - amino acid residues (866-1105) Tetanus neurotoxin - amino acid residues (882-1127)

[0233] Preferred Clostridial Neurotoxin H C Domains are described herein.

[0234] Clostridial neurotoxin H CThe domain may comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 8, 22, 30, 38, 42, 44, 46, 48, or 50, or a fragment thereof. C The domain comprises a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 8, 22, 30, 38, 42, 44, 46, 48, or 50, or a fragment thereof. Preferably, the domain is a Clostridial neurotoxin H C A domain comprises (more preferably consists of) a polypeptide sequence comprising any one of SEQ ID NOs: 8, 22, 30, 38, 42, 44, 46, 48, or 50, or a fragment thereof.

[0235] Clostridial neurotoxin H C The domain can be encoded by a nucleotide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 7, 21, 29, 37, 41, 43, 45, 47, or 49, or a fragment thereof. C The domain is encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 7, 21, 29, 37, 41, 43, 45, 47, or 49, or a fragment thereof. C The domain is one encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 7, 21, 29, 37, 41, 43, 45, 47, or 49, or a fragment thereof.

[0236] In one embodiment, the Clostridial neurotoxin H for use in the present invention C Domain variant BoNT / AH C domain. CThe domain can include modifications of one or more amino acid residues selected from Y1117, F1252, H1253, and L1278. For example, the variant BoNT / AH C The domain may comprise one or more (preferably two or more) of the following modifications: Y1117V, F1252Y, H1253K, and L1278F or L1278H.

[0237] In one embodiment, the variant BoNT / AH C The domain contains the following modifications: Y1117V and H1253K; or Y1117V, F1252Y, H1253K, and L1278F; or Y1117V, F1252Y, H1253K, and L1278H.

[0238] Preferably, a variant BoNT / AH C The domain contains the following modifications: Y1117V and H1253K; or Y1117V, F1252Y, H1253K, and L1278H.

[0239] The alterations may be alterations relative to unaltered BoNT / A, shown as SEQ ID NO: 62. Amino acid residue numbering is determined by alignment with SEQ ID NO: 62. Because the presence of a methionine residue at position 1 of SEQ ID NO: 62 is optional, one skilled in the art would take the presence / absence of the methionine residue into account when determining the amino acid residue numbering. For example, where SEQ ID NO: 62 includes a methionine, the position numbering would be as defined above (e.g., Y1117 would align with Y1117 of SEQ ID NO: 62). Alternatively, where a methionine is absent from SEQ ID NO: 62, the amino acid residue numbering should be altered by -1 (e.g., Y1117 would align with Y1116 of SEQ ID NO: 52). Similar considerations apply when a methionine is present / absent at position 1 of the other polypeptide sequences described herein, and one skilled in the art would have no difficulty determining the correct amino acid residue numbering using techniques routine in the art.

[0240] Variant BoNT / AH CA domain can comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 46, 48, or 50, or a fragment thereof, except that variant BoNT / AH C The domain contains the modifications described above. In one embodiment, the variant BoNT / AH C A domain comprises a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 46, 48, or 50, or a fragment thereof, except that a variant BoNT / AH C The domain contains the modifications described above. In one embodiment, the variant BoNT / AH C A domain comprises a polypeptide sequence having at least 99% or 99.9% sequence identity to any one of SEQ ID NOs: 46, 48, or 50, or a fragment thereof, except that a variant BoNT / AH C The domain contains the modifications described above. Preferably, the variant BoNT / AH C A domain comprises (more preferably consists of) a polypeptide sequence comprising any one of SEQ ID NOs: 46, 48, or 50, or a fragment thereof.

[0241] Variant BoNT / AH C A domain can comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 46 or 50, or a fragment thereof, except that variant BoNT / AH C The domain contains the modifications described above. In one embodiment, the variant BoNT / AH C A domain comprises a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 46 or 50, or a fragment thereof, except that a variant BoNT / AH C The domain contains the modifications described above. In one embodiment, the variant BoNT / AH CA domain comprises a polypeptide sequence having at least 99% or 99.9% sequence identity to any one of SEQ ID NOs: 46 or 50, or a fragment thereof, except that a variant BoNT / AH C The domain contains the modifications described above. Preferably, the variant BoNT / AH C The domain comprises (more preferably consists of) a polypeptide sequence comprising any one of SEQ ID NOs: 46 or 50, or a fragment thereof.

[0242] Variant BoNT / AH C The domain can be encoded by a nucleotide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 45, 47, or 49, or a fragment thereof, except that variant BoNT / AH C The domain contains the modifications described above. In one embodiment, the variant BoNT / AH C The domain is encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 45, 47, or 49, or a fragment thereof, except that the variant BoNT / AH C The domain contains the modifications described above. In one embodiment, the variant BoNT / AH C The domain is encoded by a nucleotide sequence having at least 99% or 99.9% sequence identity to any one of SEQ ID NOs: 45, 47, or 49, or a fragment thereof, except that the variant BoNT / AH C The domain contains the modifications described above. Preferably, the variant BoNT / AH C The domain is one encoded by any one of SEQ ID NOs: 45, 47, or 49, or a fragment thereof.

[0243] Variant BoNT / AH CThe domain can be encoded by a nucleotide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 45 or 49, or a fragment thereof, except that variant BoNT / AH C The domain contains the modifications described above. In one embodiment, the variant BoNT / AH C The domain is encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 45 or 49, or a fragment thereof, except that the variant BoNT / AH C The domain contains the modifications described above. In one embodiment, the variant BoNT / AH C The domain is encoded by a nucleotide sequence having at least 99% or 99.9% sequence identity to any one of SEQ ID NOs: 45 or 49, or a fragment thereof, except that the variant BoNT / AH C The domain contains the modifications described above. Preferably, the variant BoNT / AH C The domain is one encoded by any one of SEQ ID NOs: 45 or 49, or a fragment thereof.

[0244] Any of the facilitation domains described above can be combined with any of the previously described translocation domain peptides suitable for use in the present invention. Thus, by way of example, a non-clostridial facilitation domain can be combined with a non-clostridial translocation domain peptide or with a clostridial translocation domain peptide. Alternatively, a clostridial neurotoxin H CN The translocation-facilitating domain may be combined with a non-clostridial translocation domain peptide. Alternatively, a clostridial neurotoxin H CN The facilitation domain may be combined with a Clostridial translocation domain peptide. Examples of these include: Botulinum type A neurotoxin - amino acid residues (449-1110) Botulinum type B neurotoxin - amino acid residues (442-1097) Botulinum type C neurotoxin - amino acid residues (450-1111) Botulinum type D neurotoxin - amino acid residues (446-1098) Botulinum type E neurotoxin - amino acid residues (423-1085) Botulinum type F neurotoxin - amino acid residues (440-1105) Botulinum type G neurotoxin - amino acid residues (447-1105) Tetanus neurotoxin - amino acid residues (458-1127)

[0245] In some embodiments, the clostridial neurotoxin of the present invention comprises a functional H C In one embodiment, the clostridial neurotoxin preferably lacks the last 50 C-terminal amino acids of the clostridial neurotoxin holotoxin. In another embodiment, the clostridial neurotoxin preferably lacks the last 100, preferably the last 150, more preferably the last 200, particularly preferably the last 250, and most preferably the last 300 C-terminal amino acid residues of the clostridial neurotoxin holotoxin. Alternatively, the clostridial neurotoxin may lack the last 50 C-terminal amino acid residues of the clostridial neurotoxin holotoxin. C The binding activity can be abolished / reduced by mutagenesis - for example, referring to BoNT / A for convenience, the modification of one or two amino acid residues (W1266 to L and Y1267 to F) on the ganglioside binding pocket can abolish / reduce the binding activity of H C This causes the region to lose its receptor-binding function. Analogous mutations can be made in non-serotype A clostridial peptide components, such as constructs based on botulinum B (W1262 to L and Y1263 to F) or botulinum E (W1224 to L and Y1225 to F) with mutations. Other mutations in the active site, such as Y1267S in botulinum type A toxin and the corresponding highly conserved residues in other clostridial neurotoxins, can be made by replacing H Cachieve the same reduction in receptor binding activity. Details of this and other mutations are described in Rummel et al (2004) (Molecular Microbiol. 51: 631-634), which is incorporated herein by reference.

[0246] Native clostridial neurotoxin H C The peptide contains approximately 400-440 amino acid residues and is divided into two functionally distinct domains of approximately 25 kDa each: the N-terminal region (usually H CN peptide or domain) and the C-terminal region (usually H CC It consists of a peptide or domain. This fact is confirmed by the following publications, each of which is incorporated herein by reference in its entirety: Umland TC (1997) Nat. Struct. Biol. 4: 788-792; Herreros J (2000) Biochem. J. 347: 199-204; Halpern J (1993) J. Biol. Chem. 268: 15, pp. 11188-11192; Rummel A (2007) PNAS 104: 359-364; Lacey DB (1998) Nat. Struct. Biol. 5: 898-902; Knapp (1998) Am. Cryst. Assoc. Abstract Papers 25: 90; Swaminathan and Eswaramoorthy (2000) Nat. Struct. Biol. 7: 1751-1759; and Rummel A (2004) Mol. Microbiol. 51(3), 631-643. Furthermore, the C-terminal region (H CC It is well established that the heavy chain H is responsible for binding of clostridial neurotoxins to their native cellular receptors, i.e., to the nerve endings at the neuromuscular junction—a fact also confirmed by the above publications. Therefore, herein, we refer to the heavy chain H as a functional heavy chain H that is unable to bind to the cell surface receptor to which native clostridial neurotoxins bind. CThe term "clostridial heavy chain lacking a peptide (or domain)" means that the clostridial heavy chain is simply a functional H CC In other words, to reduce its native binding capacity to nerve endings at the neuromuscular junction, CC Peptide regions can be deleted or otherwise modified (eg, by conventional chemical or proteolytic treatment), either partially or entirely.

[0247] Therefore, in one embodiment, the Clostridial neurotoxin H of the present invention N The peptides consist of the C-terminal peptide portion (H CC ) and therefore lacks the H of native clostridial neurotoxins. C By way of example, in one embodiment, the C-terminally extended Clostridium H N The peptide lacks the C-terminal 40, 60, 80, 100, 120, 140, 150, or 160 amino acid residues of the clostridial neurotoxin heavy chain. N The peptides consist of the entire C-terminal peptide portion of the clostridial neurotoxin (H CC ) and therefore lacks the H of native clostridial neurotoxins. C By way of example, in one embodiment, Clostridium H N The peptide lacks the C-terminal 165 amino acid residues, or the C-terminal 170 amino acid residues, or the C-terminal 175 amino acid residues, or the C-terminal 180 amino acid residues, or the C-terminal 185 amino acid residues, or the C-terminal 190 amino acid residues, or the C-terminal 195 amino acid residues of the Clostridial neurotoxin heavy chain. N The peptide is a Clostridium H selected from the group consisting of: CC Lacking a reference sequence: Botulinum type A neurotoxin - amino acid residues (Y1111-L1296) Botulinum type B neurotoxin - amino acid residues (Y1098-E1291) Botulinum type C neurotoxin - amino acid residues (Y1112-E1291) Botulinum type D neurotoxin - amino acid residues (Y1099-E1276) Botulinum type E neurotoxin - amino acid residues (Y1086-K1252) Botulinum type F neurotoxin - amino acid residues (Y1106-E1274) Botulinum type G neurotoxin - amino acid residues (Y1106-E1297) Tetanus neurotoxin - amino acid residues (Y1128-D1315).

[0248] The reference sequences identified above should be considered as a guide, as minor variations may occur according to serosubtype.

[0249] In a preferred embodiment, the clostridial neurotoxin of the present invention comprises (or consists of) a clostridial neurotoxin L chain or a fragment thereof and a clostridial neurotoxin H chain fragment. For example, the clostridial neurotoxin comprises a clostridial neurotoxin L chain or a fragment thereof and a clostridial neurotoxin translocation domain (H N Preferably, the clostridial neurotoxin further comprises (or consists of) a clostridial neurotoxin receptor binding domain (H C ) or at least the C-terminal portion of the Clostridial neurotoxin receptor-binding domain (H CC ) in one embodiment. Therefore, in one embodiment, the clostridial neurotoxin of the present invention does not contain the C-terminal portion (H CC Advantageously, such clostridial neurotoxins lack endogenous clostridial neurotoxin receptor binding ability and therefore exhibit fewer off-target effects in subjects administered said clostridial neurotoxin.

[0250] In one embodiment, the clostridial neurotoxin of the present invention essentially consists of a clostridial neurotoxin L chain or a fragment thereof and / or a clostridial neurotoxin H chain fragment. The term "essentially consisting of" used in this context means that the clostridial neurotoxin does not further contain one or more amino acid residues that impart additional functionality to the clostridial neurotoxin when, for example, it is administered to a subject. In other words, a clostridial neurotoxin "essentially consisting of" a clostridial neurotoxin L chain or a fragment thereof and / or a clostridial neurotoxin H chain fragment may further contain one or more amino acid residues (to those of the clostridial neurotoxin L chain or a fragment thereof and / or a clostridial neurotoxin H chain fragment), but said one or more additional amino acid residues do not impart additional functionality to the clostridial neurotoxin when, for example, it is administered to a subject. The additional functionality may include any enzymatic activity, binding activity, and / or any physiological activity.

[0251] In one embodiment, a clostridial neurotoxin may contain a non-clostridial neurotoxin sequence in addition to any clostridial neurotoxin sequence. The non-clostridial neurotoxin sequence preferably does not block the ability of the clostridial neurotoxin of the present invention to promote a neuroimmune response. Preferably, the non-clostridial neurotoxin sequence does not have catalytic activity, e.g., enzymatic activity. Preferably, the non-clostridial sequence does not bind to a cellular receptor. In other words, most preferably, the non-clostridial sequence is not a ligand for a cellular receptor. The cellular receptor may be a proteinaceous cellular receptor, such as an integral membrane protein. Examples of cellular receptors can be found in the IUPHAR Guide to Pharmacology Database, version 2019.4, available at https: / / www.guidetopharmacology.org / download.jsp#db_reports. The non-clostridial neurotoxin sequence may include a tag to aid in purification, such as a His tag. Preferably, any Clostridial neurotoxin sequence contained in the Clostridial neurotoxin consists of a Clostridial neurotoxin L chain or a fragment thereof and / or a fragment of a Clostridial neurotoxin H chain. In one embodiment, the Clostridial neurotoxin sequence contained in the Clostridial neurotoxin may consist of a Clostridial neurotoxin L chain. In one embodiment, the Clostridial neurotoxin sequence contained in the Clostridial neurotoxin may consist of a Clostridial neurotoxin translocation domain. In one embodiment, the Clostridial neurotoxin sequence contained in the Clostridial neurotoxin may consist of a Clostridial neurotoxin receptor-binding domain. In one embodiment, the Clostridial neurotoxin sequence contained in the Clostridial neurotoxin may consist of a Clostridial neurotoxin L chain and a Clostridial neurotoxin translocation domain.

[0252] Suitable clostridial neurotoxins comprising (or consisting of) a clostridial neurotoxin light chain and translocation domain are described herein.

[0253] A clostridial neurotoxin comprising (or consisting of) a clostridial neurotoxin L chain and a translocation domain may comprise a polypeptide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 4, 20, 28, or 36, or a fragment thereof. In one embodiment, a clostridial neurotoxin comprising (or consisting of) a clostridial neurotoxin L chain and a translocation domain comprises a polypeptide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 4, 20, 28, or 36, or a fragment thereof. Preferably, a clostridial neurotoxin comprising (or consisting of) a clostridial neurotoxin L chain and a translocation domain comprises (more preferably consists of) a polypeptide sequence comprising any one of SEQ ID NOs: 4, 20, 28, or 36, or a fragment thereof.

[0254] A clostridial neurotoxin comprising (or consisting of) a clostridial neurotoxin L chain and a translocation domain may be encoded by a nucleotide sequence having at least 70% sequence identity to any one of SEQ ID NOs: 3, 19, 27, or 35, or a fragment thereof. In one embodiment, a clostridial neurotoxin comprising (or consisting of) a clostridial neurotoxin L chain and a translocation domain is encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to any one of SEQ ID NOs: 3, 19, 27, or 35, or a fragment thereof. Preferably, a clostridial neurotoxin comprising (or consisting of) a clostridial neurotoxin L chain and a translocation domain is encoded by a nucleotide sequence comprising any one of SEQ ID NOs: 3, 19, 27, or 35, or a fragment thereof.

[0255] The clostridial neurotoxins of the present invention may be free of complexing proteins present in naturally occurring clostridial neurotoxin complexes.

[0256] The clostridial neurotoxins of the present invention can be produced using recombinant nucleic acid technology. Thus, in one embodiment, the clostridial neurotoxin (as described above) is a recombinant clostridial neurotoxin.

[0257] In one embodiment, a clostridial neurotoxin of the present invention comprises a clostridial neurotoxin L chain. Preferably, the L chain is catalytically inactive.

[0258] The active clostridial neurotoxin L chain has non-cytotoxic protease activity. Specifically, the active clostridial neurotoxin L chain has endopeptidase activity and can cleave proteins of the exocytic fusion apparatus in target cells. The proteins of the exocytic fusion apparatus are preferably SNARE proteins, such as SNAP-25, synaptobrevin / VAMP, or syntaxin.

[0259] The term "catalytically inactive" as used herein with respect to a clostridial neurotoxin L chain means that the L chain exhibits substantially no non-cytotoxic protease activity. Preferably, the term "catalytically inactive" as used herein with respect to a clostridial neurotoxin L chain means that the L chain exhibits substantially no non-cytotoxic protease activity. In one embodiment, a catalytically inactive clostridial neurotoxin L chain does not cleave proteins of the exocytosis fusion apparatus in a target cell. The term "substantially no non-cytotoxic protease activity" means that the clostridial neurotoxin L chain has less than 5% of the non-cytotoxic protease activity of a catalytically active clostridial neurotoxin L chain, for example, less than 2%, 1%, or preferably less than 0.1% of the non-cytotoxic protease activity of a catalytically active clostridial neurotoxin L chain. Non-cytotoxic protease activity can be determined in vitro by incubating a test Clostridial neurotoxin L chain with a SNARE protein and comparing the amount of SNARE protein cleaved by the test Clostridial neurotoxin L chain to the amount of SNARE protein cleaved by a catalytically active Clostridial neurotoxin L chain under the same conditions. Conventional techniques such as SDS-PAGE and Western blotting can be used to quantify the amount of cleaved SNARE protein. A suitable in vitro assay is described in WO 2019 / 145577 A1, which is incorporated herein by reference.

[0260] Cell-based and in vivo assays can also be used to determine whether a Clostridial neurotoxin containing an L chain and a functional cell binding and translocation domain has non-cytotoxic protease activity. Assays such as the digit abduction score (DAS), dorsal root ganglion (DRG) assay, spinal cord neuron (SCN) assay, and mouse phrenic nerve hemidiaphragm (PNHD) assay are routine in the art. Suitable assays for determining non-cytotoxic protease activity can be those described in Donald et al. (2018), Pharmacol Res Perspective, e00446, 1-14, which is incorporated herein by reference.

[0261] A catalytically inactive L chain can have one or more mutations that inactivate the catalytic activity. For example, a catalytically inactive BoNT / AL chain can contain mutations of active site residues, such as His223, Glu224, His227, Glu262, and / or Tyr366. Position numbering corresponds to the amino acid positions of SEQ ID NO:62 and can be determined by aligning the polypeptide with SEQ ID NO:62. Because the presence of a methionine residue at position 1 of SEQ ID NO:62 is optional, one skilled in the art would take the presence / absence of the methionine residue into account when determining the amino acid residue numbering. For example, where SEQ ID NO:62 includes a methionine, the position numbering would be as defined above (e.g., His223 would be His223 in SEQ ID NO:62). Alternatively, where a methionine is absent in SEQ ID NO:62, the amino acid residue numbering should be modified by -1 (e.g., His223 would be His222 in SEQ ID NO:62). Similar considerations apply when a methionine at position 1 of the other polypeptide sequences described herein is present / absent, and one of skill in the art will have no difficulty determining the correct amino acid residue numbering using routine techniques in the art.

[0262] In a particularly preferred embodiment, the clostridial neurotoxin of the present invention is a modified BoNT / A or a fragment thereof (preferably, BoNT / AH). Cdomain or fragment thereof). A modified BoNT / A or fragment thereof can contain a modification at one or more amino acid residue(s) selected from the following: ASN886, ASN905, GLN915, ASN918, GLU920, ASN930, ASN954, SER955, GLN991, GLU992, GLN995, ASN1006, ASN1025, ASN1026, ASN1032, ASN1043, ASN1046, ASN1052, ASP1058, HIS1064, ASN1080, GLU1081, GLU1083, ASP1086, ASN1188, ASP1213, GLY1215, ASN1216, GLN1229, ASN1242, ASN1243, SER1274, and THR1277. Such modified BoNT / As or fragments thereof may demonstrate reduced or absent side effects compared to the use of known BoNT / As. The increased tissue retention properties of the modified BoNT / As of the present invention may also provide increased potency and / or duration of action, allowing reduced dosages (or increased dosages without any additional adverse effects) to be used compared to known clostridial toxin therapeutics, and therefore may provide further advantages.

[0263] The modification may be a modification compared to unmodified BoNT / A, set forth as SEQ ID NO: 62. Amino acid residue numbering is determined by alignment with SEQ ID NO: 62. Because the presence of a methionine residue at position 1 of SEQ ID NO: 62 (and SEQ ID NOs corresponding to the modified BoNT / A polypeptides or fragments thereof described herein) is optional, one skilled in the art would take the presence / absence of the methionine residue into consideration when determining the amino acid residue numbering. For example, where SEQ ID NO: 62 includes a methionine, the position numbering would be as defined above (e.g., ASN886 would be ASN886 in SEQ ID NO: 62). Alternatively, where a methionine is absent from SEQ ID NO: 62, the amino acid residue numbering should be modified by -1 (e.g., ASN886 would be ASN885 in SEQ ID NO: 62). Similar considerations apply when a methionine is present / absent at position 1 of the other polypeptide sequences described herein, and one skilled in the art would have no difficulty determining the correct amino acid residue numbering using techniques routine in the art.

[0264] The amino acid residue(s) indicated for modification above are surface-exposed amino acid residue(s).

[0265] The modified BoNT / A or fragment thereof can include a modification at one or more amino acid residue(s) selected from the following: ASN886, ASN930, ASN954, SER955, GLN991, ASN1025, ASN1026, ASN1052, ASN1188, ASP1213, GLY1215, ASN1216, GLN1229, ASN1242, ASN1243, SER1274, and THR1277.

[0266] The term "one or more amino acid residue(s)," when used in the context of a modified BoNT / A or a fragment thereof, preferably refers to at least 2, 3, 4, 5, 6, or 7 of the indicated amino acid residue(s). Thus, a modified BoNT / A can contain at least 2, 3, 4, 5, 6, or 7 (preferably 7) modifications to the indicated amino acid residue(s). A modified BoNT / A or a fragment thereof can contain 1 to 30, 3 to 20, or 5 to 10 amino acid modifications. More preferably, the term "one or more amino acid residue(s)," when used in the context of a modified BoNT / A or a fragment thereof, refers to all of the indicated amino acid residue(s).

[0267] Preferably, other than the one or more amino acid modification(s) at the indicated amino acid residue(s), the modified BoNT / A or fragment thereof does not contain any additional amino acid modifications when compared to SEQ ID NO:62.

[0268] The modification may be selected from the following: i. Substitution of an acidic surface-exposed amino acid residue with a basic amino acid residue; ii. Substitution of acidic surface-exposed amino acid residues with uncharged amino acid residues; iii. Substitution of uncharged surface-exposed amino acid residues with basic amino acid residues; iv. insertion of a basic amino acid residue; and v. Deletion of acidic surface-exposed amino acid residues.

[0269] The modifications indicated above result in a modified BoNT / A or fragment thereof having an increased positive surface charge and an increased isoelectric point when compared to the corresponding unmodified BoNT / A or fragment thereof.

[0270] The isoelectric point (pI) is a specific property of a given protein. As is well known in the art, proteins are made up of specific sequences of amino acids (also referred to as amino acid residues when on a protein). Each amino acid in the standard set of 20 has a different side chain (or R group), meaning that each amino acid residue on a protein exhibits different chemical properties, such as charge and hydrophobicity. These properties can be affected by the surrounding chemical environment, such as temperature and pH. The overall chemical characteristics of a protein will depend on the sum of these various factors.

[0271] Certain amino acid residues (discussed in more detail below) possess ionizable side chains that can assume a charge depending on the surrounding pH. Whether such a side chain is charged at a given pH depends on the pKa of the ionizable moiety in question, which is the negative logarithm of the acid dissociation constant (Ka) for a given proton from the conjugate base.

[0272] For example, acidic residues such as aspartic acid and glutamic acid have side chain carboxylic acid groups with pKa values ​​of approximately 4.1 (the exact pKa value may depend on temperature, ionic strength, and the microenvironment of the ionizable group). Therefore, these side chains display a negative charge at a pH of 7.4 (often referred to as "physiological pH"). At lower pH values, these side chains will become protonated and lose their charge.

[0273] Conversely, basic residues such as lysine and arginine have nitrogen-containing side chains with pKa values ​​of approximately 10-12. Thus, these side chains display a positive charge at a pH of 7.4. These side chains will become deprotonated and lose their charge at higher pH values.

[0274] Thus, the overall (net) charge of a protein molecule depends on the number of acidic and basic residues present on the protein (and their surface exposure) as well as the surrounding pH. Changing the surrounding pH changes the overall charge on the protein. Thus, for each protein, there is a given pH at which the number of positive and negative charges is equal and the protein exhibits no overall net charge. This point is known as the isoelectric point (pI). Isoelectric point is a standard concept in protein biochemistry and will be familiar to those skilled in the art.

[0275] Thus, the isoelectric point (pI) is defined as the pH value at which a protein exhibits a net charge of zero. An increase in pI means that a higher pH value is required for the protein to exhibit a net charge of zero. Therefore, an increase in pI represents an increase in the net positive charge of the protein at a given pH. Conversely, a decrease in pI means that a lower pH value is required for the protein to exhibit a net charge of zero. Therefore, a decrease in pI represents a decrease in the net positive charge of the protein at a given pH.

[0276] Methods for determining the pI of a protein are known in the art and will be familiar to those skilled in the art. As an example, the pI of a protein can be calculated from the average pKa value of each amino acid present on the protein ("calculated pI"). Such calculations can be performed using computer programs known in the art, such as the Compute-pI / MW tool from ExPASy (https: / / web.expasy.org / compute_pi / ). This is a preferred method for calculating pI according to the present invention. Comparisons of pI values ​​between different molecules should be made using the same calculation technique / program.

[0277] Where appropriate, the calculated pI of a protein can be confirmed experimentally using the technique of isoelectric focusing ("observed pI"). This technique uses electrophoresis to separate proteins according to their pI. Isoelectric focusing is typically performed using a gel with an immobilized pH gradient. When an electric field is applied, the protein migrates through the pH gradient until it reaches a pH at which it has a net charge of zero. This point is the protein's pI. The results provided by isoelectric focusing are typically relatively low resolution in nature; therefore, the inventors believe that results provided by calculated pIs (as described above) are more appropriate to use.

[0278] In this specification, unless otherwise stated, "pI" means "calculated pI."

[0279] The pI of a protein can be increased or decreased by modulating the number of basic and / or acidic groups present on its surface. This can be achieved by modifying one or more amino acids of the protein. For example, an increase in pI can be provided by reducing the number of acidic residues or by increasing the number of basic residues.

[0280] A modified BoNT / A or fragment thereof of the present invention can have a pI value that is at least 0.2, 0.4, 0.5, or 1 pI unit higher than that of an unmodified BoNT / A (e.g., SEQ ID NO: 62) or fragment thereof. Preferably, the modified BoNT / A or fragment thereof can have a pI of at least 6.6, e.g., at least 6.8.

[0281] The properties of the 20 common amino acids are indicated in the table below: [Table 2]

[0282] The following amino acids are considered charged amino acids: aspartic acid (negative), glutamic acid (negative), arginine (positive), and lysine (positive).

[0283] At a pH of 7.4, the side chains of aspartic acid (pKa 3.1) and glutamic acid (pKa 4.1) are negatively charged, while the side chains of arginine (pKa 12.5) and lysine (pKa 10.8) are positively charged. Aspartic acid and glutamic acid are called acidic amino acid residues. Arginine and lysine are called basic amino acid residues.

[0284] The following amino acids are considered uncharged polar (meaning they can participate in hydrogen bonding) amino acids: asparagine, glutamine, histidine, serine, threonine, tyrosine, cysteine, methionine, and tryptophan.

[0285] The following amino acids are considered uncharged hydrophobic amino acids: alanine, valine, leucine, isoleucine, phenylalanine, proline, and glycine.

[0286] In an amino acid insertion, an additional amino acid residue (one not normally present) is incorporated onto a BoNT / A polypeptide sequence or fragment thereof, thereby increasing the total number of amino acid residues on said sequence. In an amino acid deletion, an amino acid residue is removed from a Clostridial toxin amino acid sequence, thereby reducing the total number of amino acid residues on said sequence.

[0287] Preferably, the modification is a substitution, which advantageously maintains the same number of amino acid residues on the modified BoNT / A or fragment thereof. In an amino acid substitution, an amino acid residue that forms part of the BoNT / A polypeptide sequence or fragment thereof is replaced with a different amino acid residue. The replacement amino acid residue can be one of the 20 standard amino acids described above. Alternatively, the replacement amino acid in an amino acid substitution can be a non-standard amino acid (an amino acid that is not part of the 20 standard set described above). By way of example, the replacement amino acid can be a basic non-standard amino acid, such as L-ornithine, L-2-amino-3-guanidinopropionic acid, or D-isomers of lysine, arginine, and ornithine. Methods for introducing non-standard amino acids into proteins are known in the art and include recombinant protein synthesis using an auxotrophic expression host, E. coli.

[0288] In one embodiment, the substitution is selected from: substitution of an acidic amino acid residue with a basic amino acid residue, substitution of an acidic amino acid residue with an uncharged amino acid residue, and substitution of an uncharged amino acid residue with a basic amino acid residue. In one embodiment where the substitution is substitution of an acidic amino acid residue with an uncharged amino acid residue, the acidic amino acid residue is replaced by its corresponding uncharged amide amino acid residue (i.e., aspartic acid is replaced by asparagine, glutamic acid is replaced by glutamine).

[0289] Preferably, the basic amino acid residue is a lysine or arginine residue. In other words, the substitution is with lysine or arginine. Most preferably, the modification is with lysine.

[0290] Preferably, the modified BoNT / A or fragment thereof for use in the present invention is Clostridial toxin H CNThe modified BoNT / A or fragment thereof preferably contains between 4 and 40 amino acid modifications located on the domain. The modified BoNT / A or fragment thereof also preferably has a pI of at least 6.6. The modified BoNT / A preferably contains at least four amino acid modifications selected from the following: ASN886, ASN930, ASN954, SER955, GLN991, ASN1025, ASN1026, and ASN1052. The modifications include amino acid substitutions with lysine or arginine residues. For example, the modified BoNT / A or fragment thereof can contain at least five amino acid modifications selected from the following: ASN886, ASN930, ASN954, SER955, GLN991, ASN1025, ASN1026, ASN1052, and GLN1229. The modifications include amino acid substitutions with lysine or arginine residues.

[0291] Methods for modifying proteins by substitution, insertion, or deletion of amino acid residues are known in the art. For example, amino acid modifications can be introduced by modifying the DNA sequence encoding the polypeptide (e.g., encoding unmodified BoNT / A or a fragment thereof). This can be accomplished using standard molecular cloning techniques. For example, by site-directed mutagenesis, in which a short strand of DNA (oligonucleotide) encoding the desired amino acid(s) is used to replace the original coding sequence using a polymerase enzyme, or by inserting / deleting portions of a gene with various enzymes (e.g., ligases and restriction endonucleases). Alternatively, modified gene sequences can be chemically synthesized.

[0292] In one embodiment, a clostridial neurotoxin for use in accordance with the present invention comprises a polypeptide having at least 80%, 90%, 95%, or 98% sequence identity to SEQ ID NO: 42. Preferably, a clostridial neurotoxin for use in accordance with the present invention comprises the polypeptide sequence set forth as SEQ ID NO: 42.

[0293] In one embodiment, a clostridial neurotoxin for use in accordance with the present invention comprises a polypeptide sequence encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to SEQ ID NO: 41. Preferably, a clostridial neurotoxin for use in accordance with the present invention comprises a polypeptide sequence encoded by the nucleotide sequence set forth as SEQ ID NO: 41.

[0294] In one embodiment, a clostridial neurotoxin for use in accordance with the present invention (e.g., comprising or encoded by SEQ ID NO: 42) may be a portion of a polypeptide having at least 70% sequence identity to SEQ ID NO: 61 or 65. Thus, in one embodiment, a clostridial neurotoxin for use in accordance with the present invention may comprise a polypeptide having at least 80%, 90%, 95%, or 98% sequence identity to SEQ ID NO: 61 or 65. Preferably, a clostridial neurotoxin for use in accordance with the present invention may comprise (more preferably consist of) SEQ ID NO: 61 or 65. In one embodiment, a clostridial neurotoxin comprises a catalytically inactive L chain (e.g., according to SEQ ID NO: 65).

[0295] In one embodiment, a clostridial neurotoxin for use in accordance with the present invention (e.g., comprising SEQ ID NO: 42 or encoded by SEQ ID NO: 41) may be encoded by a nucleotide sequence having at least 70% sequence identity to SEQ ID NO: 60. Thus, in one embodiment, a clostridial neurotoxin for use in accordance with the present invention may be encoded by a nucleotide sequence having at least 80%, 90%, 95%, or 98% sequence identity to SEQ ID NO: 60. Preferably, a clostridial neurotoxin for use in accordance with the present invention may be encoded by a nucleotide sequence comprising (more preferably consisting of) SEQ ID NO: 60. In one embodiment, a clostridial neurotoxin comprises a catalytically inactive L chain.

[0296] SEQ ID NO: 42 is an example of a modified BoNT / A fragment, and SEQ ID NOs: 61 and 65 are examples of catalytically active and inactive modified BoNT / A polypeptides, respectively. Such modified BoNT / A polypeptides and fragments are particularly preferred for use in the present invention. The polypeptides set forth as SEQ ID NOs: 42, 61, and 62 have several amino acid modifications (e.g., substitutions) compared to wild-type BoNT / A, which increase the isoelectric point of the polypeptide. Without wishing to be bound by theory, it is believed that the increased net positive charge promotes electrostatic interactions between the polypeptide and anionic extracellular components, thereby promoting binding between the polypeptide and the cell surface and therefore increasing retention at the site of administration and / or duration of action. Therefore, it is postulated that the neuroimmune response-promoting properties of SEQ ID NOs: 42, 61, and 65 will be improved compared to equivalent polypeptides lacking the aforementioned modifications.

[0297] For the catalytically active modified BoNT / A polypeptide described above (e.g., SEQ ID NO: 61), one way in which these advantageous properties (which represent an increased therapeutic index) can be defined is in terms of the safety factor of the modified BoNT / A. In this regard, the undesired effects of clostridial neurotoxins (caused by diffusion of the toxin from the administration site) can be experimentally evaluated by measuring the percentage of body weight loss in a relevant animal model (e.g., mice in which weight loss is detected within 7 days of administration). Conversely, the desired on-target effects of clostridial neurotoxins can be experimentally evaluated by the digit abduction score (DAS) assay, a measure of muscle paralysis. The DAS assay can be performed by injecting 20 μl of clostridial neurotoxin formulated in gelatin phosphate buffer into the mouse gastrocnemius / soleus muscle complex, followed by evaluation of the digit abduction score using the method of Aoki (Aoki KR, Toxicon 39: 1815-1820; 2001). In the DAS assay, mice are briefly suspended by their tails to elicit a characteristic startle response, in which they extend their hind limbs and abduct their hind digits. After clostridial neurotoxin injection, varying degrees of digit abduction are scored on a 5-point scale (0 = normal to 4 = maximal reduction in digit abduction and paw extension).

[0298] The safety factor of a clostridial neurotoxin can then be expressed as the ratio between the amount of toxin required for a 10% drop in body weight (measured in mice at peak effect within the first 7 days after dosing) and the amount of toxin required for a DAS score of 2. Thus, a high safety factor score is desirable and indicates a toxin capable of effectively paralyzing target muscles with few unwanted off-target effects. The catalytically active modified BoNT / A of the present invention can have a safety factor higher than that of a comparable unmodified (native) botulinum toxin (e.g., SEQ ID NO: 62).

[0299] Therefore, in one embodiment, a catalytically active modified BoNT / A of the invention has a safety factor of at least 8 (e.g., at least 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, or 50), where the safety factor is calculated as: ED of DAS 50 The dose of toxin required for a 10% change in body weight (pg / mouse) [ED 50 dose required to produce a DAS score of = 2].

[0300] In one embodiment, a catalytically active modified BoNT / A of the invention has a safety factor of at least 10. In one embodiment, a modified BoNT / A or fragment thereof of the invention has a safety factor of at least 15.

[0301] A clostridial neurotoxin comprising at least 70% sequence identity to SEQ ID NO: 61 is described in WO 2015 / 004461 A1, which is incorporated herein by reference in its entirety.

[0302] In one embodiment, a clostridial neurotoxin comprising a polypeptide sequence having at least 70% sequence identity to SEQ ID NO:42, 61, or 65 and / or comprising a polypeptide sequence encoded by a nucleotide sequence having at least 70% sequence identity to SEQ ID NO:41 or 60 contains substitutions at one or more (preferably two or more, three or more, four or more, five or more, or six or more, more preferably all) of positions 930, 955, 991, 1026, 1052, 1229, and 886. Position numbering corresponds to positions in SEQ ID NO:62 and can be determined by aligning the polypeptide sequence with SEQ ID NO:62 (unmodified / wild-type BoNT / A). Because the presence of a methionine residue at position 1 in SEQ ID NO:62 is optional, one skilled in the art would take the presence / absence of the methionine residue into consideration when determining amino acid residue numbering. For example, where SEQ ID NO:62 includes a methionine, the position numbering would be as defined above (e.g., position 886 would be ASN886 of SEQ ID NO:62). Alternatively, where methionine is absent in SEQ ID NO: 62, the amino acid residue numbering should be modified by -1 (e.g., position 886 would be ASN 885 in SEQ ID NO: 62). Similar considerations apply when methionine is present / absent at position 1 of the other polypeptide sequences described herein, and one of skill in the art would have no difficulty determining the correct amino acid residue numbering using routine techniques in the art.

[0303] Preferably, a clostridial neurotoxin comprising a polypeptide sequence having at least 70% sequence identity to SEQ ID NO: 42, 61, or 65 and / or comprising a polypeptide sequence encoded by a nucleotide sequence having at least 70% sequence identity to SEQ ID NO: 41 or 60 comprises a lysine or arginine (more preferably, lysine) at one or more of positions 930, 955, 991, 1026, 1052, 1229, and 886. In one embodiment, the clostridial neurotoxin comprises a lysine or arginine (more preferably, lysine) at the smallest two, three, four, five, six, or all of positions 930, 955, 991, 1026, 1052, 1229, and 886. Most preferably, the clostridial neurotoxin comprises a lysine or arginine (more preferably, lysine) at all of positions 930, 955, 991, 1026, 1052, 1229, and 886.

[0304] It is intended that embodiments of the invention relating to various therapeutic uses apply equally to methods of treatment, polypeptides, of the invention, and vice versa.

[0305] sequence homology

[0306] Any of a variety of sequence alignment methods can be used to determine percent identity, including, without limitation, global methods, local methods, and hybrid methods, such as segment approach methods. Protocols for determining percent identity are routine procedures within the skill of the art. Global methods align multiple sequences from the beginning to the end of the molecule and determine the best alignment by summing the scores of individual residue pairs and by imposing gap penalties. Non-limiting methods include, for example: CLUSTAL-W, see, e.g., Julie D. Thompson et al., CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting, Position-Specific Gap Penalties and Weight Matrix Choice, 22(22) Nucleic Acids Research 4673-4680 (1994); and iterative refinement methods, see, e.g., Osamu Gotoh, Significant Improvement in Accuracy of Multiple Proteins. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments, 264(4) J. Mol. Biol. 823-838 (1996). Local methods align multiple sequences by identifying one or more conserved motifs shared by all of the input sequences. Non-limiting methods include, for example, the following:Match-box, see e.g., Eric Depiereux and Ernest Feytmans, Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences, 8(5) CABIOS 501-509 (1992); Gibbs sampling, see e.g., C.E. Lawrence et al., Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment, 262(5131) Science 208-214 (1993); Align-M, see e.g., Ivo Van Walle et al., Align-M - A New Algorithm for Multiple Alignment of Highly Divergent Sequences, 20(9) Bioinformatics:1428-1435 (2004).

[0307] Thus, percent sequence identity is determined by conventional methods. See, e.g., Altschul et al., Bull. Math. Bio. 48: 603-16, 1986 and Henikoff and Henikoff, Proc. Natl. Acad. Sci. USA 89: 10915-19, 1992. Briefly, as shown below, two amino acid sequences are aligned to optimize the alignment score using a gap open penalty of 10, a gap extension penalty of 1, and the "blosum62" scoring matrix of Henikoff and Henikoff (ibid.) (amino acids are designated by standard single-letter codes):

[0308] The "percent sequence identity" between two or more nucleic acid or amino acid sequences is a function of the number of identical positions shared by multiple sequences.Therefore, percent identity can be calculated as the number of identical nucleotides / amino acids multiplied by 100 divided by the total number of nucleotides / amino acids.The calculation of percent sequence identity can also take into account the number of gaps and the length of each gap that need to be introduced to optimize the alignment of two or more sequences.The sequence comparison and percent identity determination between two or more sequences can be performed using specific mathematical algorithms such as BLAST.Those skilled in the art will be familiar with this.

[0309]

number

[0310] The percent identity is then calculated as: [total number of identical matches × 100] / [length of the longer sequence plus the number of gaps introduced in the longer sequence to align the two sequences]

[0311] Substantially homologous polypeptides are characterized as having one or more amino acid substitutions, deletions, or additions. These changes are preferably minor in nature, i.e., conservative amino acid substitutions (see below) and other substitutions that do not significantly affect the folding or activity of the polypeptide; small deletions, typically from 1 to about 30 amino acids; and small amino- or carboxyl-terminal extensions, such as an amino-terminal methionine residue, a small linker peptide of up to about 20-25 residues, or an affinity tag.

[0312] Conservative amino acid substitutions Basic: arginine, lysine, histidine Acidic: glutamic acid, aspartic acid Polarity: Glutamine, Asparagine Hydrophobic: leucine, isoleucine, valine Aromatic: phenylalanine, tryptophan, tyrosine Small: glycine, alanine, serine, threonine, methionine

[0313] In addition to the 20 standard amino acids, non-standard amino acids (e.g., 4-hydroxyproline, 6-N-methyllysine, 2-aminoisobutyric acid, isovaline, and α-methylserine) can be substituted for amino acid residues in the polypeptides of the invention. A limited number of non-conservative amino acids, amino acids not encoded by the genetic code, and unnatural amino acids can be substituted for polypeptide amino acid residues. The polypeptides of the invention can also include non-naturally occurring amino acid residues.

[0314] Non-naturally occurring amino acids include, without limitation, trans-3-methylproline, 2,4-methanoproline, cis-4-hydroxyproline, trans-4-hydroxyproline, N-methylglycine, allothreonine, methylthreonine, hydroxyethylcysteine, hydroxyethylhomocysteine, nitroglutamine, homoglutamine, pipecolic acid, tert-leucine, norvaline, 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, and 4-fluorophenylalanine. Several methods for incorporating non-naturally occurring amino acid residues into proteins are known in the art. For example, an in vitro system can be employed in which nonsense mutations are suppressed using chemically aminoacylated suppressor tRNAs. Methods for synthesizing amino acids and aminoacylating tRNAs are known in the art. Transcription and translation of plasmids containing nonsense mutations are performed in a cell-free system containing an S30 extract of E. coli and commercially available enzymes and other reagents. Proteins are purified by chromatography. (See, e.g., Robertson et al., J. Am. Chem. Soc. 113: 2722, 1991; Ellman et al., Methods Enzymol. 202: 301, 1991; Chung et al., Science 259: 806-9, 1993; and Chung et al., Proc. Natl. Acad. Sci. USA 90: 10145-9, 1993.) In a second method, translation is carried out in Xenopus oocytes by microinjection of mutated mRNA and chemically aminoacylated suppressor tRNA (Turcatti et al., J. Biol. Chem. 271: 19991-8, 1996). In the third method, E. coli cells are cultured in the absence of the natural amino acid to be replaced (e.g., phenylalanine) and in the presence of the desired non-naturally occurring amino acid(s) (e.g., 2-azaphenylalanine, 3-azaphenylalanine, 4-azaphenylalanine, or 4-fluorophenylalanine).Non-naturally occurring amino acids are incorporated into polypeptides in place of their natural counterparts. See Koide et al., Biochem. 33: 7470-6, 1994. Naturally occurring amino acid residues can be converted to non-naturally occurring species by in vitro chemical modification. Chemical modification can be combined with site-directed mutagenesis to further expand the range of substitutions (Wynn and Richards, Protein Sci. 2:395-403, 1993).

[0315] A limited number of non-conservative amino acids, amino acids that are not encoded by the genetic code, non-naturally occurring amino acids, and unnatural amino acids may be substituted for amino acid residues in the polypeptides of the invention.

[0316] Essential amino acids on the polypeptides of the invention can be identified according to procedures known in the art, such as site-directed mutagenesis or alanine scanning mutagenesis (Cunningham and Wells, Science 244: 1081-5, 1989). Sites of biological interaction can also be determined by physical analysis of structures determined by techniques such as nuclear magnetic resonance, crystallography, electron diffraction, or photoaffinity labeling, along with mutations of putative contact site amino acids. See, e.g., de Vos et al., Science 255: 306-12, 1992; Smith et al., J. Mol. Biol. 224: 899-904, 1992; Wlodaver et al., FEBS Lett. 309: 59-64, 1992. The identity of essential amino acids can also be inferred from analysis of homology with related components of the polypeptides of the invention (e.g., translocation or protease components).

[0317] Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-7, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-6, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions on a polypeptide, selecting functional polypeptides, and then sequencing the mutagenized polypeptides to determine the spectrum of permissible substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., Biochem. 30: 10832-7, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92 / 06204) and region-directed mutagenesis (Derbyshire et al., Gene 46: 145, 1986; Ner et al., DNA 7: 127, 1988).

[0318] Multiple amino acid substitutions can be made and tested using known methods of mutagenesis and screening, such as those disclosed by Reidhaar-Olson and Sauer (Science 241:53-7, 1988) or Bowie and Sauer (Proc. Natl. Acad. Sci. USA 86:2152-6, 1989). Briefly, these authors disclose methods for simultaneously randomizing two or more positions on a polypeptide, selecting functional polypeptides, and then sequencing the mutagenized polypeptides to determine the spectrum of permissible substitutions at each position. Other methods that can be used include phage display (e.g., Lowman et al., Biochem. 30: 10832-7, 1991; Ladner et al., U.S. Patent No. 5,223,409; Huse, WIPO Publication WO 92 / 06204) and region-directed mutagenesis (Derbyshire et al., Gene 46: 145, 1986; Ner et al., DNA 7: 127, 1988).

[0319] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Singleton, et al., DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY, 20 ED., John Wiley and Sons, New York (1994) and Hale & Marham, THE HARPER COLLINS DICTIONARY OF BIOLOGY, Harper Perennial, NY (1991) provide those skilled in the art with a comprehensive dictionary of many of the terms used in this disclosure.

[0320] The present disclosure is not limited by the exemplary methods and materials disclosed herein, and any methods and materials similar or equivalent to those described herein can be used to practice or test embodiments of the present disclosure. Numerical ranges include the numbers that define the range. Unless otherwise indicated, each nucleic acid sequence is written from left to right in 5' to 3' orientation; amino acid sequences are written from left to right in amino to carboxy orientation, respectively.

[0321] The headings provided herein are not limitations of the various aspects or embodiments of the disclosure.

[0322] Amino acids are referred to herein using the amino acid name, three-letter abbreviation, or one-letter abbreviation. As used herein, the term "protein" encompasses proteins, polypeptides, and peptides. As used herein, the term "amino acid sequence" is synonymous with the term "polypeptide" and / or the term "protein." In some cases, the term "amino acid sequence" is synonymous with the term "peptide." In some cases, the term "amino acid sequence" is synonymous with the term "enzyme." The terms "protein" and "polypeptide" are used interchangeably herein. In this disclosure and claims, conventional one-letter and three-letter codes for amino acid residues may be used. The three-letter codes for amino acids are as defined in accordance with the IUPACIUB Joint Commission on Biochemical Nomenclature (JCBN). It is also understood that a polypeptide can be encoded by more than one nucleotide sequence due to the degeneracy of the genetic code.

[0323] Other definitions of terms may appear herein. Before exemplary embodiments are described in more detail, it should be understood that the present disclosure is not limited to the particular embodiments described, and as such may vary. It should also be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present disclosure is defined only by the appended claims.

[0324] Where a range of values ​​is provided, it is understood that each intervening value between the upper and lower limits of that range is also specifically disclosed, to the tenth of the unit of the lower limit, unless the context clearly dictates otherwise. Each smaller range between any claimed or intervening value within a claimed range and any other claimed or intervening value within that claimed range is encompassed within the disclosure. The upper and lower limits of these smaller ranges may independently be included or excluded in the range. Subject to any specifically excluded limit within the claimed range, each range in which either or both limits are included in the smaller range, or neither, is also encompassed within the disclosure. Where a claimed range includes one or both of the limits, ranges excluding either or both of those included limits are also encompassed within the disclosure.

[0325] It should be pointed out that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to a "clostridial neurotoxin" includes a plurality of such agents, reference to a "clostridial neurotoxin" includes reference to one or more clostridial neurotoxins and equivalents thereof known to those skilled in the art, and so forth.

[0326] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application, and nothing herein should be construed as an admission that such publications constitute prior art to the claims appended hereto.

[0327] Embodiments of the present invention will now be described, by way of example only, with reference to the following figures and examples. [Brief explanation of the drawings]

[0328] [Figure 1] Schematic diagram of the positioning of the imaging area in the study. [Figure 2] Graph showing laser injury-induced changes in microglial density in area 1. In Dysport-treated mice, more microglia migrated towards the lesion site (increasing microglial cell density). [Figure 3] Graph showing laser-induced activation changes in the mean sphericity index of microglia in Area 1. Activated microglia have a lower sphericity index (cell body shape is more elongated). [Figure 4] Graph showing changes in fluorescence after laser-induced microglial process outgrowth (outliers removed; scar formation in area 1): The microglial response was significantly stronger at 42 minutes in Dysport-treated mice.

[0329] Sequence Listing

[0330] Wherever the first Met amino acid residue or the corresponding first codon is indicated in any of the following SEQ ID NOs, said residue / codon is optional. SEQ ID NO: 1 - Nucleotide sequence of recombinant catalytically inactive BoNT / A (rBoNT / A(0)) SEQ ID NO:2 - Polypeptide sequence of rBoNT / A(0) SEQ ID NO:3 - rLH NNucleotide sequence of / A (light chain plus translocation domain only) SEQ ID NO:4 - rLH N Polypeptide sequence of / A SEQ ID NO: 5 - Nucleotide sequence of rL / A (light chain only) SEQ ID NO: 6 - Polypeptide sequence of rL / A SEQ ID NO:7 - rH C Nucleotide sequence of / A SEQ ID NO:8 - rH C Polypeptide sequence of / A SEQ ID NO: 9 - Nucleotide sequence of rBoNT / B(0) SEQ ID NO: 10 - Polypeptide sequence of rBoNT / B(0) SEQ ID NO: 11 - Nucleotide sequence of rBoNT / C(0) SEQ ID NO: 12 - Polypeptide sequence of rBoNT / C(0) SEQ ID NO: 13 - Nucleotide sequence of rBoNT / E(0) SEQ ID NO: 14 - Polypeptide sequence of rBoNT / E(0) SEQ ID NO: 15 - Nucleotide sequence of rBoNT / F(0) SEQ ID NO: 16 - Polypeptide sequence of rBoNT / F(0) SEQ ID NO: 17 - Nucleotide sequence of rBoNT / A(0) (His-tagged) SEQ ID NO: 18 - Polypeptide sequence of rBoNT / A(0) (His-tagged) SEQ ID NO: 19 - rLH N Nucleotide sequence of / A (His-tagged) SEQ ID NO: 20 - rLH N Polypeptide sequence of / A (His-tagged) SEQ ID NO: 21 - rH C Nucleotide sequence of / A (His-tagged) SEQ ID NO: 22 - rH C Polypeptide sequence of / A (His-tagged) SEQ ID NO: 23 - Nucleotide sequence of rLC / A (His tagged) SEQ ID NO: 24 - Polypeptide sequence of rLC / A (His tagged) SEQ ID NO: 25 - Nucleotide sequence of rBoNT / FA(0) (His-tagged) SEQ ID NO: 26 - Polypeptide sequence of rBoNT / FA(0) (His-tagged) SEQ ID NO: 27 - rLH N Nucleotide sequence of / FA (His-tagged) SEQ ID NO: 28 - rLH N Polypeptide sequence of / FA (His tagged) SEQ ID NO: 29 - rH C Nucleotide sequence of / FA (His-tagged) SEQ ID NO: 30 - rH C Polypeptide sequence of / FA (His tagged) SEQ ID NO: 31 - Nucleotide sequence of rLC / FA (His tagged) SEQ ID NO: 32 - Polypeptide sequence of rLC / FA (His tagged) SEQ ID NO: 33 - Nucleotide sequence of rBoNT / F(0) (His-tagged) SEQ ID NO: 34 - Polypeptide sequence of rBoNT / F(0) (His-tagged) SEQ ID NO: 35 - rL H Nucleotide sequence of N / F (His-tagged) SEQ ID NO: 36 - rL H N / F (His-tagged) polypeptide sequence SEQ ID NO: 37 - rH C Nucleotide sequence of / F (His-tagged) SEQ ID NO: 38 - rH C Polypeptide sequence of / F (His tagged) SEQ ID NO: 39 - Nucleotide sequence of rLC / F (His tagged) SEQ ID NO: 40 - Polypeptide sequence of rLC / F (His tagged) SEQ ID NO: 41 - cationic rH C Nucleotide sequence of / A (His-tagged) SEQ ID NO: 42 - cationic rH C Polypeptide sequence of / A (His-tagged) SEQ ID NO: 43 - rHC Nucleotide sequence of / AB (His-tagged) SEQ ID NO: 44 - rH C Polypeptide sequence of / AB (His-tagged) SEQ ID NO: 45 - rH C Nucleotide sequence of / A variant Y1117V H1253K (His-tagged) SEQ ID NO: 46 - rH C Polypeptide sequence of / A variant Y1117V H1253K (His-tagged) SEQ ID NO: 47 - rH C Nucleotide sequence of / A variant Y1117V F1252Y H1253K L1278F (His-tagged) SEQ ID NO: 48 - rH C Polypeptide sequence of / A variant Y1117V F1252Y H1253K L1278F (His-tagged) SEQ ID NO: 49 - rH C Nucleotide sequence of / A variant Y1117V F1252Y H1253K L1278H (His-tagged) SEQ ID NO: 50 - rH C Polypeptide sequence of / A variant Y1117V F1252Y H1253K L1278H (His-tagged) SEQ ID NO: 51 - Polypeptide sequence of BoNT / A - UniProt P10845 SEQ ID NO: 52 - Polypeptide sequence of BoNT / B - UniProt P10844 SEQ ID NO: 53 - Polypeptide sequence of BoNT / C - UniProt P18640 SEQ ID NO: 54 - Polypeptide sequence of BoNT / D - UniProt P19321 SEQ ID NO: 55 - Polypeptide sequence of BoNT / E - UniProt Q00496 SEQ ID NO: 56 - Polypeptide sequence of BoNT / F - UniProt A7GBG3 SEQ ID NO: 57 - Polypeptide sequence of BoNT / G - UniProt Q60393 SEQ ID NO: 58 - Polypeptide sequence of TeNT - UniProt P04958 SEQ ID NO: 59 - Polypeptide sequence of BoNT / X SEQ ID NO: 60 - Nucleotide sequence of mrBoNT / A SEQ ID NO: 61 - Polypeptide sequence of mrBoNT / A SEQ ID NO: 62 - Polypeptide sequence of unmodified BoNT / A1 SEQ ID NO: 63 - Polypeptide sequence of mrBoNT / AB SEQ ID NO: 64 - Polypeptide sequence of mrBoNT / AB(0) SEQ ID NO: 65 - Polypeptide sequence of mrBoNT / A(0)

[0331] SEQ ID NO: 1 - Nucleotide sequence, rBoNT / A(0)

[0332] SEQ ID NO:2 - Polypeptide sequence, rBoNT / A(0)

[0333] SEQ ID NO:3 - nucleotide sequence, rLH N / A

[0334] SEQ ID NO: 4 - Polypeptide sequence, rLH N / A MEFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLT SIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAV TLAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSG KFSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVDGIITSKT KSDDDDKNKALNLQCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKY TMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIF SGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDD LSSKLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTLEAHHHHHHHHHH

[0335] SEQ ID NO: 5 - nucleotide sequence, rL / A

[0336] SEQ ID NO: 6 - Polypeptide sequence, rL / A MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTS IVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTL AHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGKFS VDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLGLEAHHHHHHHHHH

[0337] SEQ ID NO: 7 - nucleotide sequence, rH C / A

[0338] SEQ ID NO:8 - Polypeptide sequence, rH C / A MHHHHHHKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENN SGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKEL NEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVK NKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL

[0339] SEQ ID NO: 9 - Nucleotide sequence, rBoNT / B(0)

[0340] SEQ ID NO: 10 - Polypeptide sequence, rBoNT / B(0)

[0341] SEQ ID NO: 11 - Nucleotide sequence, rBoNT / C(0)

[0342] SEQ ID NO: 12 - Polypeptide sequence, rBoNT / C(0)

[0343] SEQ ID NO: 13 - Nucleotide sequence, rBoNT / E(0)

[0344] SEQ ID NO: 14 - Polypeptide sequence, rBoNT / E(0)

[0345] SEQ ID NO: 15 - Nucleotide sequence, rBoNT / F(0)

[0346] SEQ ID NO: 16 - Polypeptide sequence, rBoNT / F(0)

[0347] SEQ ID NO: 17 - Nucleotide sequence, rBoNT / A(0) (His-tagged)

[0348] SEQ ID NO: 18 - Polypeptide sequence, rBoNT / A(0) (His tagged)

[0349] SEQ ID NO: 19 - nucleotide sequence, rLH N / A (His-tagged)

[0350] SEQ ID NO: 20 - Polypeptide sequence, rLH N / A (His-tagged) MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTS IVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVT LAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGK FSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKS LDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTMF HYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEAAMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSGA VILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSS KLNESINKAMININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIPFQLSKYVDNQRLLSTENLYFQGASHHHHHHHH

[0351] SEQ ID NO: 21 - nucleotide sequence, rH C / A (His-tagged)

[0352] SEQ ID NO: 22 - Polypeptide sequence, rH C / A (His-tagged) MHHHHHHENLYFQGKNIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIIN CMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFD KELNEKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVV KNKEYRLATNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL

[0353] SEQ ID NO: 23 - Nucleotide sequence, rLC / A (His tagged)

[0354] SEQ ID NO: 24 - Polypeptide sequence, rLC / A (His tagged) MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTS IVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVT LAHELIHAGHRLYGIAINPNRVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKAKSIVGTTASLQYMKNVFKEKYLLSEDTSGK FSVDKLKFDKLYKMLTEIYTEDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFTGLFEENLYFQGASHHHHHHHH

[0355] SEQ ID NO: 25 - Nucleotide sequence, rBoNT / FA(0) (His-tagged)

[0356] SEQ ID NO: 26 - Polypeptide sequence, rBoNT / FA(0) (His tagged)

[0357] SEQ ID NO: 27 - nucleotide sequence, rLH N / FA (His-tagged)

[0358] SEQ ID NO: 28 - Polypeptide sequence, rLH N / FA (His-tagged) MPVVINSFNYDDPVNDNTIIYIRPPYYETSNTYFKAFQIMDNVWIIPERYRLGIDPSLFNPPVSLKAGSDGYFDPNYLSTNTEKNKYLQIMIKLFKRINSKPAGQILLE EIKNAIPYLGNSYTQEEQFTTNNRTVSFNVKLANGNIVQQMANLIIWGPGPDLTTNKTGGIIYSPYQSMEATPYKDGFGSIMTVEFSPEYATAFNDISIASHSPSLFIKD PALILMHELIHVLHGLYGTYITEYKITPNVVQSYMKVTKPITSAEFLTFGGRDRNIVPQSIQSQLYNKVLSDYKRIASRLNKVNTATALINIDEFKNLYEWKYQFAKDS NGVYSVDLNKFEQLYKKIYSFTEFNLAYEFKIKTRLGYLAENFGPFYLPNLLDDSIYTEVDGFNIGALSINYQGQNIGSDINSIKKLQGQGVVSRVVRLCSNSNTKNSLC ITVNNRDLFFIASQESYGENTINTYKEIDDTTTLDPSFEDILDKVILNFNEQVIPQMPNRNVSTDIQKDNYIPKYDYNRTDIIDSYEVGRNYNTFFYLNAQKFSPNESN ITLTSSFDTGLLEGSKVYTFFSSDFINNINKPVQALLFIEWVKQVIRDFTTEATKTSTVDKLKDISLVVPYIGLALNIGDEIYKQHFAEAVELVGAGLLLEFSPEFLIPT LLIFTIKGYLTGSIRDKDKIIKTLDNALNVRDQKWKELYRWVVSKWLTTINTQFNKRKEQMYKALKNQATAIKKIIENKYNNYTTDEKSKIDSSYNINEIERTLNEKINL AMKNIEQFITESSIAYLINIINNETIQKLKSYDDLVRRYLLGYIRNHSSILGNSVEELNSKVNNHLDNGIPFELSSYTNDSLLIRYFNKNYGEENLYFQGASHHHHHHHH

[0359] SEQ ID NO: 29 - nucleotide sequence, rH C / FA (His-tagged)

[0360] SEQ ID NO: 30 - Polypeptide sequence, rH C / FA (His-tagged) MLKYNCILNIKYEMDRDKLVDSSGYRSRINIGTGVKFSEIDKNQVQLSNLESSKIEVILNNGVIYNSMYENFSTSFWIRIPKYFRNINNEYKIISCMQNNSGWEVSLNFSN MNSKIIWTLQDTEGIKKTVVFQYTQNINISDYINRWIFVTITNNRLSNSKIYINGRLINEESISDLGNIHASNNIMFKLDGCRDPHRYIWIKYFNLFDKELNKKEIKDLYDN QSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYLDVNNVGIRGYMYLKGPRGRIVTTNIYLNSTLYMGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQAG VEKILSAVEIPDVGNLSQVVVMKSENDQGIRNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIGKASRTFGCSWEFIPVDDGWGESSLENLYFQGASHHHHHHHH

[0361] SEQ ID NO: 31 - Nucleotide sequence, rLC / FA (His tagged)

[0362] SEQ ID NO: 32 - Polypeptide sequence, rLC / FA (His tagged) MPVVINSFNYDDPVNDNTIIYIRPPYYETSNTYFKAFQIMDNVWIIPERYRLGIDPSLFNPPVSLKAGSDGYFDPNYLSTNTEKNKYLQIMIKLFKRINSKPAGQILLEEIK NAIPYLGNSYTQEEQFTTNNRTVSFNVKLANGNIVQQMANLIIWGPGPDLTTNKTGGIIYSPYQSMEATPYKDGFGSIMTVEFSPEYATAFNDISIASHSPSLFIKDPALIL MHELIHVLHGLYGTYITEYKITPNVVQSYMKVTKPITSAEFLTFGGRDRNIVPQSIQSQLYNKVLSDYKRIASRLNKVNTATALINIDEFKNLYEWKYQFAKDSNGVYSVDL NKFEQLYKKIYSFTEFNLAYEFKIKTRLGYLAENFGPFYLPNLLDDSIYTEVDGFNIGALSINYQGQNIGSDINSIKKLQGQGVVSRVVRLCSNSENLYFQGASHHHHHHHH

[0363] SEQ ID NO: 33 - Nucleotide sequence, rBoNT / F(0) (His-tagged)

[0364] SEQ ID NO: 34 - Polypeptide sequence, rBoNT / F(0) (His tagged)

[0365] SEQ ID NO: 35 - nucleotide sequence, rL H N / F (His-tagged)

[0366] SEQ ID NO: 36 - Polypeptide sequence, rL H N / F (His-tagged) MPVVINSFNYNDPVNDDTILYMQIPYEEKSKKYYKAFEIMRNVWIIPERNTIGTDPSDFDPPASLENGSSAYYDPNYLTTDAEKDRYLKTTIKLFKRINSNPAGEVLLQE ISYAKPYLGNEHTPINEFHPVTRTTSVNIKSSTNVKSSIILNLLVLGAGPDIFENSSYPVRKLMDSGGVYDPSNDGFGSINIVTFSPEYEYTFNDISGGYNSSTESFIAD PAISLAHELIHALHGLYGARGVTYKETIKVKQAPLMIAEKPIRLEEFLTFGQDLNIITSAMKEKIYNNLLANYEKIATRLSRVNSAPPEYDINEYKDYFQWKYGLDKNA DGSYTVNENKFNEIYKKLYSFTEIDLANKFKVKCRNTYFIKYGFLKVPNLLDDDIYTVSEGFNIGNLAVNNRGQNIKLNPKIIDSIPDKGLVEKIVKFCKSVIPRKGTKAP PRLCIRVNNRELFFVASESSYNENDINTPKEIDDTTNLNNNYRNNLDEVILDYNSETIPQISNQTLNTLVQDDSYVPRYDSNGTSEIEEHNVVDLNVFFYLHAQKVPEGE TNISLTSSIDTALSEESQVYTFFSSEFINTINKPVHAALFISWINQVIRDFTTEATQKSTFDKIADISLVVPYVGLALNIGNEVQKENFKEAFELLGAGILLEFVPELLI PTILVFTIKSFIGSSENKNKIIKAINNSLMERETKWKEIYSWIVSNWLTRINTQFNKRKEQMYQALQNQVDAIKTVIEYKYNNYTSDERNRLESEYNINNIREELNKKVS LAMENIERFITESSIFYLMKLINEAKVSKLREYDEGVKEYLLDYISEHRSILGNSVQELNDLVTSTLNNSIPFELSSYTNDKILILYFNKLYKKENLYFQGASHHHHHHHH

[0367] SEQ ID NO: 37 - nucleotide sequence, rH C / F (His-tagged)

[0368] SEQ ID NO: 38 - Polypeptide sequence, rH C / F (His-tagged) MIKDNSILDMRYENNKFIDISGYGSNISINGDVYIYSTNRNQFGIYSSKPSEVNIAQNNDIIYNGRYQNFSISFWVRIPKYFNKVNLNNEYTIIDCIRNNNNSGWKIS LNYNKIIWTLQDTAGNNQKLVFNYTQMISISDYINKWIFVTITNNRLGNSRIYINGNLIDEKSISNLGDIHVSDNILFKIVGCNDTRYVGIRYFKVFDTELGKTEIET LYSDEPDPSILKDFWGNYLLYNKRYYLLNLLRTDKSITQNSNFLNINQQRGVYQKPNIFSNTRLYTGVEVIIRKNGSTDISNTDNFVRKNDLAYINVVDRDVEYRLYA DISIAKPEKIIKLIRTSNSNNSLGQIIVMDSIGNNCTMNFQNNNGGNIGLLGFHSNNLVASSWYYNNIRKNTSSNGCFWSFISKEHGWQENENLYFQGASHHHHHHHH

[0369] SEQ ID NO: 39 - Nucleotide sequence, rLC / F (His tagged)

[0370] SEQ ID NO: 40 - Polypeptide sequence, rLC / F (His tagged) MPVVINSFNYNDPVNDDTILYMQIPYEEKSKKYYKAFEIMRNVWIIPERNTIGTDPSDFDPPASLENGSSAYYDPNYLTTDAEKDRYLKTTIKLFKRINSNPAGEVLLQEIS YAKPYLGNEHTPINEFHPVTRTTSVNIKSSTNVKSSIILNLLVLGAGPDIFENSSYPVRKLMDSGGVYDPSNDGFGSINIVTFSPEYEYTFNDISGGYNSSTESFIADPAIS LAHELIHALHGLYGARGVTYKETIKVKQAPLMIAEKPIRLEEFLTFGQDLNIITSAMKEKIYNNLLANYEKIATRLSRVNSAPPEYDINEYKDYFQWKYGLDKNADGSYTV NENKFNEIYKKLYSFTEIDLANKFKVKCRNTYFIKYGFLKVPNLLDDDIYTVSEGFNIGNLAVNNRGQNIKLNPKIIDSIPDKGLVEKIVKFCKSENLYFQGASHHHHHHHH

[0371] SEQ ID NO: 41 - nucleotide sequence, cationic rH C / A (His-tagged)

[0372] SEQ ID NO: 42 - Polypeptide sequence, cationic rH C / A (His-tagged) MIINTSILNLRYESKHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKKAIVYNSMYENFSTSFWIRIPKYFNKISLNNEYTIINCMENNSGWKVSLNY GEIIWTLQDTKEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNKSKIYINGRLIDQKPISNLGNIHASNKIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDN QSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQ AGVEKILSALEIPDVGNLSQVVVMKSKNDKGITNKCKMNLQDNNGNDIGFIGFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPLKLAAALEHHHHHH

[0373] SEQ ID NO: 43 - nucleotide sequence, rH C / AB (His-tagged)

[0374] SEQ ID NO: 44 - Polypeptide sequence, rH C / AB (His-tagged) MILNNIILNLRYKDNNLIDLSGYGAKVEVYDGVELNDKNQFKLTSSANSKIRVTQNQNIIFNSVFLDFSVSFFWIRIPKYKNDGIQNYIHNEYTIINCMKNNSGWKISIRGN RIIWTLIDINGKTKSVFFEYNIREDISEYINRWFFVTITNNLNNAKIYINGKLESNTDIKDIREVIANGEIIFKLDGDIDRTQFIWMKYFSIFNTELSQSNIEERYKIQSYS EYLKDFWGNPLMYNKEYYMFNAGNKNSYIKLKKDSPVGEILTRSKYNQNSKYINYRDLYIGEKFIIRRKSNSQSINDDIVRKEDYIYLDFFNLNQEWRVYTYKYFKKEEMK LFLAPIYDSDEFYNTIQIKEYDEQPTYSCQLLFKKDEESTDEIGLIGIHRFYESGIVFEEYKDYFCISKWYLKEVKRKPYNLKLGCNWQFIPKDEGWTEKLAAALEHHHHHH

[0375] SEQ ID NO: 45 - nucleotide sequence, rH C / A variant Y1117V H1253K (His-tagged)

[0376] SEQ ID NO: 46 - Polypeptide sequence, rH C / A variant Y1117V H1253K (His-tagged) MIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLN YGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLY DNQSNSGILKDFWGDYLQYDKPYYMLNLVDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNA SQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFKQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPLHHHHHHHHHH

[0377] SEQ ID NO: 47 - nucleotide sequence, rH C / A variant Y1117V F1252Y H1253K L1278F (His-tagged)

[0378] SEQ ID NO: 48 - Polypeptide sequence, rH C / A variant Y1117V F1252Y H1253K L1278F (His-tagged) MIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSLN YGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLY DNQSNSGILKDFWGDYLQYDKPYYMLNLVDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNA SQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNNGDIGFIGYKQFNNIAKLVASNWYNRQIERSSRTFGCSWEFIPVDDGWGERPLHHHHHHHHHH

[0379] SEQ ID NO: 49 - nucleotide sequence, rH C / A variant Y1117V F1252Y H1253K L1278H (His-tagged)

[0380] SEQ ID NO: 50 - Polypeptide sequence, rH C / A variant Y1117V F1252Y H1253K L1278H (His-tagged) MIINTSILNLRYESNHLIDLSRYASKINIGSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNNEYTIINCMENNSGWKVSL NYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTITNNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKD LYDNQSNSGILKDFWGDYLQYDKPYYMLNLVDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLA TNASQAGVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNNGDIGFIGYKQFNNIAKLVASNWYNRQIERSSRTHGCSWEFIPVDDGWGERPLHHHHHH

[0381] SEQ ID NO: 51 - Polypeptide sequence, BoNT / A - UniProt P10845 MPFVNKQFNYKDPVNGVDIAYIKIPNVGQMQPVKAFKIHNKIWVIPERDTFTNPEEGDLN PPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYSTDLGRMLLTSIVRGIPFWGG STIDTELKVIDTNCINVIQPDGSYRSEELNLVIIGPSADIIQFECKSFGHEVLNLTRNGY GSTQYIRFSPDFTFGFEESLEVDTNPLLGAGKFATDPAVTLAHELIHAGHRLYGIAINPN RVFKVNTNAYYEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYTEDNFVKFFKV LNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAANFNGQNTEINNMNFTKLKNFT GLFEFYKLLCVRGIITSKTKSLDKGYNKALNDLCIKVNNWDLFFSPSEDNFTNDLNKGEE ITSDTNIEAAEENISLDLIQQYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNG KKYELDKYTMFHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKDDFVGALIFSG AVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALSKRNEKWDEVYKYIVTNWLAK VNTQIDLIRKKMKEALENQAEATKAIINYQYNQYTEEEKNNINFNIDDLSSKLNESINKA MININKFLNQCSVSYLMNSMIPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDK VNNTLSTDIPFQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESNHLIDLSRYASKINI GSKVNFDPIDKNQIQLFNLESSKIEVILKNAIVYNSMYENFSTSFWIRIPKYFNSISLNN EYTIINCMENNSGWKVSLNYGEIIWTLQDTQEIKQRVVFKYSQMINISDYINRWIFVTIT NNRLNNSKIYINGRLIDQKPISNLGNIHASNNIMFKLDGCRDTHRYIWIKYFNLFDKELN EKEIKDLYDNQSNSGILKDFWGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPR GSVMTTNIYLNSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA GVEKILSALEIPDVGNLSQVVVMKSKNDQGITNKCKMNLQDNNGNDIGFIGFHQFNNIAK LVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL

[0382] SEQ ID NO: 52 - Polypeptide sequence, BoNT / B - UniProt P10844

[0383] SEQ ID NO: 53 - Polypeptide sequence, BoNT / C - UniProt P18640

[0384] SEQ ID NO: 54 - Polypeptide sequence, BoNT / D - UniProt P19321

[0385] SEQ ID NO: 55 - Polypeptide sequence, BoNT / E - UniProt Q00496

[0386] SEQ ID NO: 56 - Polypeptide sequence, BoNT / F - UniProt A7GBG3

[0387] SEQ ID NO: 57 - Polypeptide sequence, BoNT / G - UniProt Q60393

[0388] SEQ ID NO: 58 - Polypeptide sequence, TeNT - UniProt P04958

[0389] SEQ ID NO: 59 - Polypeptide sequence, BoNT / X MKLEINKFNYNDPIDGINVITMRPPRHSDKINKGKGPFKAFQVIKNIWIVPERYNFTNNT NDLNIPSEPIMEADAIYNPNYLNTPSEKDEFLQGVIKVLERIKSKPEGEKLLELISSSIP LPLVSNGALTLSDNETIAYQENNNIVSNLQANLVIYGPGPDIANNATYGLYSTPISNGEG TLSEVSFSPFYLKPFDESYGNYRSLVNIVNKFVKREFAPDPASTLMHELVHVTHNLYGIS NRNFYYNFDTGKIETSRQQNSLIFEELLTFGGIDSKAISSLIIKKIIETAKNNYTTLISE RLNTVTVENDLLKYIKNKIPVQGRLGNFKLDTAEFEKKLNTILFVLNESNLAQRFSILVR KHYLKERPIDPIYVNILDDNSYSTLEGFNISSQGSNDFQGQLLESSYFEKIESNALRAFI KICPRNGLLYNAIYRNSKNYLNNIDLEDKKTTSKTNVSYPCSLLNGCIEVENKDLFLISN KDSLNDINLSEEKIKPETTVFFKDKLPPQDITLSNYDFTEANSIPSISQQNILERNEELY EPIRNSLFEIKTIYVDKLTTFHFLEAQNIDESIDSSKIRVELTDSVDEALSNPNKVYSPF KNMSNTINSIETGITSTYIFYQWLRSIVKDFSDETGKIDVIDKSSDTLAIVPYIGPLLNI GNDIRHGDFVGAIELAGITALLEYVPEFTIPILVGLEVIGGELAREQVEAIVNNNALDKRD QKWAEVYNITKAQWWGTIHLQINTRLAHTYKALSRQANAIKMNMEFQLANYKGNIDDKAK IKNAISETEILLNKSVEQAMKNTEKFMIKLSNSYLTKEMIPKVQDNLKNFDLETKKTLDK FIKEKEDILGTNLSSSLRRKVSIRLNKNIAFDINDIPFSEFDDLINQYKNEIEDYEVLNL GAEDGKIKDLSGTTSDINIGSDIELADGRENKAIKIKGSENSTIKIAMNKYLRFSATDNF SISFWIKHPKPTNLLNNGIEYTLVENFNQRGWKISIQDSKLIWYLRDHNNSIKIVTPDYI AFNGWNLITITNNRSKGSIVYVNGSKIEEKDISSIWNTEVDDPIIFRLKNNRDTQAFTLL DQFSIYRKELNQNEVVKLYNYYFNSNYIRDIWGNPLQYNKKYYLQTQDKPGKGLIREYWS SFGYDYVILSDSKTITFPNNIRYGALYNGSKVLIKNSKKLDGLVRNKDFIQLEIDGYNMG ISADRFNEDTNYIGTTYGTTHDLTTDFEIIQRQEKYRNYCQLKTPYNIFHKSGLMSTETS KPTFHDYRDWVYSSAWYFQNYENLNLRKHTKTNWYFIPKDEGWDED

[0390] SEQ ID NO: 60 - Nucleotide sequence, mrBoNT / A

[0391] SEQ ID NO: 61 - Polypeptide sequence, mrBoNT / A

[0392] SEQ ID NO: 62 - Polypeptide sequence, unmodified BoNT / A1

[0393] SEQ ID NO: 63 - Polypeptide sequence, mrBoNT / AB

[0394] SEQ ID NO: 64 - Polypeptide sequence, mrBoNT / AB(0)

[0395] SEQ ID NO: 65 - Polypeptide sequence, mrBoNT / A(0) MPFVNKQFNYKDPVNGVDIAYIKIPNAGQMQPVKAFKIHNKIWVIPERDT FTNPEEGDLNPPPEAKQVPVSYYDSTYLSTDNEKDNYLKGVTKLFERIYS TDLGRMLLTSIVRGIPFWGGSTIDTELKVIDTNCINVIQPDGSYRSEELN LVIIGPSADIIQFECKSFGHEVLNLTRNGYGSTQYIRFSPDFTFGFEESL EVDTNPLLGAGKFATDPAVTLAHQLIYAGHRLYGIAINPNRVFKVNTNAY YEMSGLEVSFEELRTFGGHDAKFIDSLQENEFRLYYYNKFKDIASTLNKA KSIVGTTASLQYMKNVFKEKYLLSEDTSGKFSVDKLKFDKLYKMLTEIYT EDNFVKFFKVLNRKTYLNFDKAVFKINIVPKVNYTIYDGFNLRNTNLAAN FNGQNTEINNMNFTKLKNFTGLFEFYKLLCVRGIITSKTKSLDKGYNKAL NDLCIKVNNWDLFFSPSEDNFTNDLNKGEEITSDTNIEAAEENISLDLIQ QYYLTFNFDNEPENISIENLSSDIIGQLELMPNIERFPNGKKYELDKYTM FHYLRAQEFEHGKSRIALTNSVNEALLNPSRVYTFFSSDYVKKVNKATEA AMFLGWVEQLVYDFTDETSEVSTTDKIADITIIIPYIGPALNIGNMLYKD DFVGALIFSGAVILLEFIPEIAIPVLGTFALVSYIANKVLTVQTIDNALS KRNEKWDEVYKYIVTNWLAKVNTQIDLIRKKMKEALENQAEATKAIINYQ YNQYTEEEKNNINFNIDDLSSKLNESINKAMININKFLNQCSVSYLMNSM IPYGVKRLEDFDASLKDALLKYIYDNRGTLIGQVDRLKDKVNNTLSTDIP FQLSKYVDNQRLLSTFTEYIKNIINTSILNLRYESKHLIDLSRYASKINI GSKVNFDPIDKNQIQLFNLESSKIEVILKKAIVYNSMYENFSTSFWIRIP KYFNKISLNNEYTIINCMENNSGWKVSLNYGEIIWTLQDTKEIKQRVVFK YSQMINISDYINRWIFVTITNNRLNKSKIYINGRLIDQKPISNLGNIHAS NKIMFKLDGCRDTHRYIWIKYFNLFDKELNEKEIKDLYDNQSNSGILKDF WGDYLQYDKPYYMLNLYDPNKYVDVNNVGIRGYMYLKGPRGSVMTTNIYL NSSLYRGTKFIIKKYASGNKDNIVRNNDRVYINVVVKNKEYRLATNASQA GVEKILSALEIPDVGNLSQVVVMKSKNDKGITNKCKMNLQDNNGNDIGFI GFHQFNNIAKLVASNWYNRQIERSSRTLGCSWEFIPVDDGWGERPL [Example]

[0396] material and method

[0397] animal

[0398] Six wild-type (WT) mice were used in the pilot study; 24 CX3CR1-GFP mice (breeding pairs purchased from JAX Laboratory, USA) were used in the main study; and 12 mice were used in the imaging study. Mice were 3-5 months old at the beginning of imaging. For imaging experiments, mice were fitted with a cranial window with an access port to allow imaging and neurotoxin injection (more details below).

[0399] CX3CR1-GFP mice have been described elsewhere, see Nimmerjahn et al. (Science. 2005 May 27; 308 (5726): 1314-8), which is incorporated herein by reference.

[0400] Botulinum neurotoxin (BoNT) and control injections

[0401] BoNT / A, Dysport (abo botulinum toxin A (aboBoNT-A)), dissolved in 2 μL saline was used. In control experiments, a vehicle-only (2 μL saline) solution was used.

[0402] Intracortically administered Dysport was well tolerated: three WT mice (pilot study) received 0.5 U / animal of Dysport (dissolved in 2 μL of saline) and three WT mice received vehicle solution and were observed for clinical signs and their weights measured over two days. There were no clinical signs or behavioral changes related to neurotoxic effects, and there were no significant differences in weight between treatment groups; therefore, the 0.5 U / animal dose was approved for the main study.

[0403] In the main study, 0.5 U of Dysport (dissolved in 2 μL saline) or vehicle (2 μL saline) solution was injected (during the first imaging session) into the somatosensory cortex of mice through a silicone access port (in the cranial window). The solution was injected at a rate of 2 nL / s.

[0404] Experimental setup

[0405] Thirty days before Dysport injection (day -30), mice were fitted with a cranial window with an access port (30 days were allowed to elapse before further experimental work, allowing time for brain / neuroimmune response activity and behavior to normalize after cranial window placement). During the course of the study, animals were imaged at several time points. On day 0 (the day of cortical injection of either Dysport or vehicle), imaging was performed immediately before laser injury and at 6, 18, 30, and 42 minutes after injury. Additionally, imaging was performed on day 1 (24 hours after injection / 23.5 hours after laser injury) and day 2 (48 hours after injection / 47.5 hours after laser injury). On the day of injection (day 0), baseline imaging (imaging session #1) was performed immediately before injection. Imaging session #2 was performed one day after injection (day 1). Imaging session #3 was performed two days after injection (day 2).

[0406] Craniotomy and glass plate placement

[0407] For implantation of a cranial window with an access port (the implant replaces a small piece of skull to allow imaging and access to the brain), mice were anesthetized with ketamine / xylazine. A cranial window was inserted over the somatosensory cortex at the following coordinates: AP-1.8, ML-2.0 from bregma. A small, round-shaped piece of skull (d = 4 mm) was removed using a dental drill (HP4-917, Foredom), and the hole in the bone was covered with a round cover glass (d = 5 mm; #72296-05, Electron Microscopy Sciences). Prior to implantation of the cover glass, a small, eccentrically positioned hole was drilled in the glass and filled with silicone (Sylgard 184) to create an access port for intracortical injections over the permanent cranial window. The head plate was placed on the cover glass and fixed to the skull surface by dental cement (Rapid Repair; Dentsply) mixed with cyanoacrylate glue (Loctite 401; Henkel).

[0408] Image Acquisition Setup

[0409] Illumination: 900nm, femtosecond laser Mai-Tai broadband DeepSee.

[0410] Emission filter: Channel 2 - band pass 468~552nm for enhanced green fluorescent protein (EGFP) fluorescence.

[0411] Stacks of 60 images were collected in at least two imaging areas with a vertical step of 2 μm (total imaging depth of the stack: 120 μm). Each imaging area was 500 × 500 μm in x-y coordinates. 2 Covered the space.

[0412] To induce laser injury in area 1 (see Figure 1 for a schematic representation of the imaging area positioning), a micrometer-sized region of interest (ROI) was selected at a focal plane 25–35 micrometers deep from the cortical surface, and a 100% intensity infrared laser was applied for 5 seconds during the first hour after intracortical injection. Two-photon microscopy technology was employed to target the light (laser) intensity to specific brain regions and provide a clear focus for the laser-induced injury. In the rare case of unsuccessful laser injury induction during the first imaging session, injury induction was repeated 24 hours later.

[0413] Imaging session

[0414] During the course of the study, animals were imaged at several time points. On day 0 (the day of cortical injection of either Dysport or vehicle), images were taken immediately before laser injury and at 6, 18, 30, and 42 minutes after injury. In addition, images were taken on day 1 (24 hours after injection / 23.5 hours after laser injury) and day 2 (48 hours after injection / 47.5 hours after laser injury).

[0415] Data Processing and Analysis

[0416] After capture, image stacks were aligned using Fiji / ImageJ software. Tissue misalignment in the x, y, and z directions was compensated for using plugins in Fiji software. The aligned image stacks were used to analyze microglial cell density, morphology, and laser-induced process outgrowth using a set of plugins described below.

[0417] To analyze changes in microglial density and morphology, we used a set of mathematical morphology methods and a plugin for ImageJ, "MorphoLibJ," developed at the INRA-IJPB Modeling and Digital Imaging Laboratory. Image stacks with a thickness of 40 micrometers were included in the data analysis for Area 1 (± 20 micrometers from the slice containing the laser injury) and Area 2 (the most superficial 40 micrometers).

[0418] The following sequence of steps was implemented in the MorphoLibJ plugin: 1) The aligned image stacks were filtered using grayscale and 3D morphology filters to enhance the contrast between cells and surrounding tissues; 2) Automatic Otsu binarization was applied to all images to produce binary masks of cells (minimum size threshold 20 pixels, no maximum threshold); 3) The "Particle Analysis 3D" and "Intensity Measurement 3D" plugins were applied to the image stack to obtain numerical results.

[0419] The object count of cells (to calculate cell density), total volume, and mean volume, sphericity index of cells, and mean fluorescence intensity of cells were calculated. For the 3D analysis used in this study, the sphericity index can be defined as the ratio of the squared volume (V) to the cubed surface area (S): Sphericity=36πV 2 / S 3

[0420] To measure microglial process outgrowth toward the laser injury, two circles with diameters of 25 (small circle = sc) and 50 micrometers (large circle = bc) were drawn around the center point of the injury site, and the redistribution of fluorescence from the larger circle to the smaller circle was measured. Microglial process outgrowth was calculated using the following equation: Microglial process outgrowth = [fluorescence sc(tx) - fluorescence sc(t0)] / [fluorescence bc(t0)] Where tx = time point x, t0 = time point 0 (baseline)

[0421] Numerical data were then transferred to Microsoft Excel, MicroCal Origin, and GraphPad Prism software for statistical analysis and graph plotting. Statistical comparisons between treatment groups were performed using either the Student's t-test (for normal data distribution) or the Mann-Whitney nonparametric test (for non-normal data distribution). Statistical comparisons against baseline were performed using either the paired Student's t-test (for normal data distribution) or the Wilcoxon signed-rank test (for non-normal data distribution). The Shapiro-Wilcoxon normality test was used to test for normality of distribution.

[0422] Example 1 - Clostridial neurotoxins induce a significant increase in microglial density, a decrease in cell body sphericity, and enhanced process outgrowth

[0423] The present inventors have established a robust, controlled experimental system to examine the effect of Clostridial neurotoxin administration on the activity of neuroimmune responses following neuronal tissue damage. The system allows for the induction of precise neuronal damage in the brain, which is representative of that caused by the brain disorders described herein (e.g., neuronal tissue damage caused by, for example, the presence of a brain tumor or infection, or neuronal death due to postmortem oxygen depletion).

[0424] The system employs transgenic mice in which key immune cells (microglia) in the neuroimmune response specifically express GFP, allowing time-lapse imaging of these immune cells so that their activity in response to neuronal injury can be tracked and analyzed either in the presence or absence of clostridial neurotoxin administration. An additional advantage of the system (which employs advanced optical microscopy) is that it can be coupled with a laser to induce precise areas of neuronal injury. Further details of the system are provided in the Materials and Methods section (above).

[0425] Two imaging areas were imaged in all animals (see Figure 1 for an illustration): Area 1, closer to the injection site (distance range of 600–1000 micrometers from the edge of the area to the injection site), and Area 2 (distance of at least 1000 micrometers).

[0426] A clear GFP expression pattern consistent with the morphology of microglial cells was observed in all analyzed mice. Laser injury was induced in area 1 within 1 hour after intracortical injection of Dysport on day 0 (see Figures 1 and 2). The permanent window with an access port was validated as a reliable model for repeated post-injection imaging in the CX3CR1-GFP mouse line. For optimal imaging, superficial cortical layers were laser injured and imaged. Laser injury was successfully induced in all 12 mice.

[0427] Laser injury-induced changes in microglial density and morphology in area 1 were analyzed (see Figures 2 and 3 for analysis results). First, a statistically significant increase in microglial density was observed in Dysport-treated mice but not in vehicle-treated mice after focal laser injury (Figure 2; p<0.05 vs. baseline for all time points starting at 18 minutes for the Dysport group; p>0.05 vs. baseline for all time points for the vehicle group). During the first hour after injury, the difference in microglial density in the lesion area between groups reached statistical significance (p<0.05 between treatment groups at 18 and 42 minutes). These observations suggest increased migration of microglia into the lesion area in Dysport-treated mice during the first hour after injury.

[0428] Next, we analyzed the changes in microglial morphology in the lesion-containing area 1 to find signs of microglial activation. For this, three parameters were analyzed: mean volume, mean surface area, and mean sphericity index (Figure 3). For the first two parameters, the transformation of microglia into an activated state was associated with an increase in the value (microglial cell bodies became swollen and larger), while for the sphericity index, activation was accompanied by a decrease in the value (more elongated shape).

[0429] Both the mean volume and mean surface area were found to gradually increase after laser injury, values ​​characteristic of a more activated microglial shape. Interestingly, differences between treatment groups were observed for the mean sphericity of the cells (see Figure 3). Taken together, these data suggest that Dysport affects post-lesion changes in microglial density and sphericity, but not volume and cell surface area. In other words, Dysport may primarily enhance microglial migration toward the lesion site, rather than activation-related morphological changes.

[0430] Next, we examined the effect of Dysport injection on laser-induced microglial process outgrowth and scar formation (see Figure 4). For this analysis, we analyzed the area immediately adjacent (50 μm) to the lesion spot. A rapid increase in scar fluorescence was observed, peaking approximately 40 minutes after laser injury induction (Figure 4). A single Grubbs' outlier test was used to remove any outliers. A statistically significant difference (Dysport-treated vs. vehicle-only control) was observed at 42 minutes after injury induction (Figure 7, p-value of 0.0303 by Mann-Whitney test). At this time point, scar fluorescence was more intense in Dysport-treated mice. This is consistent with the notion that Dysport enhances microglial process outgrowth toward the lesion site.

[0431] Finally, we analyzed the density and morphology of microglia in Area 2, where no laser injury was induced (e.g., Area 2 served as a control area). Briefly, no statistically significant differences were observed between treatment groups in terms of density. In Area 2, imaging was performed at four time points: before and after intracortical injection on Day 0, on Day 1 (24 h), and on Day 2 (48 h). A decrease in the sphericity index in Area 2 was observed, suggesting microglial activation in Area 1 and, for example, migration away from the injury.

[0432] In summary, no significant effect of Dysport injection on microglia was observed in area 2, which remained intact from the perspective of the laser injury, demonstrating that the effects of Dysport occur in response to the site of injury.

[0433] Summary of results

[0434] Microglia are key players in neuroprotection and regulating neuronal cell death. Here, we investigated the effect of clostridial neurotoxin administration on injury-induced microglial activation.

[0435] Adult female CX3CR1-GFP heterozygous C57BL / 6JCRL mice (n = 24) were anesthetized prior to implantation of a permanent cranial glass window (with an injection access port) suitable for repeated in vivo two-photon imaging. Seven days later, 15 animals selected for imaging studies were anesthetized prior to injection of aboBoNT-A (0.5 U in 2 μL) or its vehicle (saline) in the somatosensory cortex ~1 h before the adjacent area received a μm-sized infrared laser injury to induce microglial activation. Imaging sessions were performed at baseline, during the first 40 min after aboBoNT-A injection (before irradiation), and after the laser injury at 10-min intervals, and again 24 and 48 h after injury.

[0436] Intracortical injection of 0.5 U of aboBoNT-A in mice was safe, did not affect behavior or weight gain, and had virtually no observable effect on microglia before laser injury. After laser injury, aboBoNT-A induced a 15-50% increase in microglial density 10-40 min after injury (p<0.05), a decrease in cell body sphericity, and enhanced process outgrowth compared to the vehicle-injected group. We did not observe significant differences in microglial density between the vehicle and aboBoNT-A groups in a "control" area of ​​the same brain (the somatosensory cortex) left intact, i.e., unaffected by laser injury.

[0437] In summary, although aboBoNT-A did not observably alter microglial morphology or density in the absence of laser injury, it significantly enhanced microglial migration and process outgrowth induced by laser injury. Therefore, aboBoNT-A can be employed to mediate upregulation of microglial activation.

[0438] All publications mentioned in the above specification are herein incorporated by reference. Various modifications and variations of the described methods and system of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific preferred embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in biochemistry and biotechnology or related fields are intended to be within the scope of the following claims. [Explanation of symbols]

[0439] [Figure 1] cover glass edge: edge of the cover glass cranial window edge: edge of the cranial window injection site: injection site Area: Area Laser injury: intact: intact [Figure 2] Microglia density: Microglia density time post injury: time after injury minutes: minutes Vehicle: Base [Figure 3] Normalized mean sphericity: Normalized mean sphericity time post injury: time after injury minutes: minutes Vehicle: Base [Figure 4] Microglia laser injury process response: Microglia laser injury process response normalized: normalized time post injury: time after injury minutes: minutes Vehicle: Base

Claims

1. A medicament comprising a Clostridial neurotoxin for use in a method of treating a brain disorder in a patient by promoting a neuroimmune response.

2. A medicament comprising a Clostridial neurotoxin for use in a method for treating brain tissue damage in a patient by promoting a neuroimmune response.

3. The pharmaceutical of claim 1 or 2, wherein the Clostridial neurotoxin promotes microglial cell activity in the brain.

4. The method of any one of claims 1 to 3, wherein the Clostridial neurotoxin promotes microglial cell migration to sites of brain tissue damage.

5. The medicament of any one of claims 1 to 4, wherein the Clostridial neurotoxin promotes microglial cell phagocytic activity at the site of brain tissue damage.

6. The method of any one of claims 1 to 5, wherein the Clostridial neurotoxin promotes microglial cell migration to sites of infection.

7. The method of any one of claims 1 to 6, wherein the Clostridial neurotoxin promotes microglial cell phagocytic activity at the site of infection.

8. The method of any one of claims 1 to 7, wherein the neuroimmune response is enhanced ≦60 minutes after administration of the Clostridial neurotoxin.

9. The method of any one of claims 1 to 7, wherein the neuroimmune response is enhanced ≦10 minutes after administration of the Clostridial neurotoxin.

10. The method of any one of claims 1 to 9, wherein the neuroimmune response is promoted for ≦48 hours after the occurrence of brain tissue damage.

11. The method of any one of claims 1 to 9, wherein the neuroimmune response is promoted for ≦24 hours after the occurrence of brain tissue damage.

12. The method of any one of claims 1 to 11, wherein the Clostridial neurotoxin is administered by local administration to the head of the patient.

13. The method of any one of claims 1 to 11, wherein the Clostridial neurotoxin is administered by local administration to the patient's head by subcutaneous or intracranial injection.

14. The method of any one of claims 1 to 11, wherein the Clostridial neurotoxin is administered by intracranial injection.

15. The method of any one of claims 1 to 14, wherein the Clostridial neurotoxin is administered before brain tissue damage occurs.

16. The method of any one of claims 1 to 14, wherein the Clostridial neurotoxin is administered ≦4 days before brain tissue damage occurs.

17. The method of any one of claims 1 to 14, wherein the Clostridial neurotoxin is administered between 1 and 3 days before brain tissue damage occurs.

18. The method of any one of claims 1 to 17, wherein the Clostridial neurotoxin is administered ≦24 hours after the onset of brain tissue damage.

19. The method of any one of claims 1 to 17, wherein the Clostridial neurotoxin is administered ≦2 hours after the onset of brain tissue damage.

20. The method of any one of claims 1 to 17, wherein the Clostridial neurotoxin is administered ≦10 minutes after the onset of brain tissue damage.

21. The pharmaceutical composition according to any one of claims 1 to 20, wherein the brain damage is caused by traumatic brain injury, cancer, infectious disease, stroke, neurodegenerative disorder, cerebral aneurysm, multiple sclerosis, anoxic injury, toxic injury, and / or metabolic injury.

22. The pharmaceutical composition according to any one of claims 1 to 20, wherein the brain damage is caused by non-traumatic brain injury.

23. The pharmaceutical composition according to any one of claims 1 to 20, wherein the brain damage is caused by cancer, an infectious disease, and / or stroke.

24. The pharmaceutical composition according to any one of claims 1 to 20, wherein the brain damage is caused by an infectious disease.

25. The pharmaceutical composition according to any one of claims 1 to 20, wherein the brain damage is caused by an infectious disease selected from encephalitis, meningitis, and brain abscess.

26. The pharmaceutical composition according to any one of claims 1 to 20, wherein the brain damage is caused by an infectious disease selected from encephalitis and meningitis.

27. The pharmaceutical composition according to any one of claims 1 to 20, wherein the brain damage is caused by stroke.

28. The pharmaceutical agent according to any one of claims 1 to 20, wherein the brain disorder is caused by a neurodegenerative disorder selected from the following: Alzheimer's disease, Parkinson's disease, Parkinson's disease-related disorders, motor neuron diseases, amyotrophic lateral sclerosis, prion diseases, Huntington's disease, spinocerebellar ataxia, ataxia, Hallervorden-Spatz disease, and frontotemporal lobar degeneration.

29. The method according to any one of claims 1 to 11 and 15 to 28, wherein the Clostridial neurotoxin is administered subcutaneously, intracranially, intrathecally, or intranasally.

30. The pharmaceutical according to any one of claims 1 to 29, wherein the Clostridial neurotoxin is a botulinum neurotoxin (BoNT).

31. The pharmaceutical according to any one of claims 1 to 30, wherein the Clostridial neurotoxin is botulinum neurotoxin serotype A (BoNT / A).

32. The method according to any one of claims 1 to 30, wherein the Clostridial neurotoxin is a chimeric neurotoxin.